+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Global Biologics Contract Manufacturing (Biopharma CDMO/Biopharma CMO/Biologics Manufacturing) Market 2022-2035 by Type of Service(s) Offered, Type of Biologic Manufactured, Type of Expression System Used, Scale of Operation, Company Size, and Key Geographical Regions

  • PDF Icon

    Report

  • 799 Pages
  • December 2023
  • Region: Global
  • Roots Analysis
  • ID: 5917606

Global Partnerships Drive Progress: Biologics Contract Manufacturing Sees Over 61% Increase in Partnerships Post-COVID-19

The global biologics contract manufacturing market is estimated to reach over $19 billion in 2023 and is expected to grow at a compound annual growth rate (CAGR) of ~9% during the forecast period.

The biologics contract manufacturing market, also known as the biopharmaceutical CMO market, is a dynamic and rapidly growing sector with a large number of players investing in research and development activities for developing new modalities, such as antibody drug conjugates, biosimilars, and cell and gene therapies. With the increased interest and gradual shift of investment from small molecule drugs to biologics, over the years, more than 250 biologic therapies and vaccines have been developed globally. Notably, biologics have higher success rates than conventional small-molecule drugs owing to lesser off-target toxicity of biologics, which is one of the key reasons of failures in small molecule drugs development. Given the ongoing scientific advancements and the rise of FDA-approved biologics, the pharmaceutical industry seems to be approaching the era of biologics. In fact, biopharmaceuticals are anticipated to play a significant role in shaping the pharmaceutical industry and will eventually serve as an integral part of traditional medicines. Moreover, the exuberant development of biologics has revolutionized the treatment of a range of therapeutic conditions, which has further contributed to the exponential growth in the current demand for biologic therapies. It is worth highlighting that numerous biologics manufacturers, including biologics CMOs, have adopted digital technologies in order to enhance their productivity and reliability of existing biologics related processes and facilities. In March 2023, Bristol Myers Squibb sent a selection of its protein-based medicines to the International Space Station with the aim to refine their production processes and improve the biomanufacturing of potent medicines.

However, the complexity of biologics, as well as the integration of emerging technologies, offer challenges for current good manufacturing practices (cGMP) for biologics. Some of the key concerns of contemporary innovators include rate of attrition of pipeline drugs / therapies, long development timelines, current facility limitations, regulatory and compliance-related issues, and inconsistencies related to the quality attributes of the final product. As a result, an increasing number of biopharmaceutical drug developers are relying on contract manufacturers that are well-equipped with expertise and advanced technologies for their GMP-based manufacturing requirements. These service providers offer end-to-end solutions, including bioprocess development and optimization, to shorten operational timelines and reduce the high costs associated with the production of complex biologic drugs. In addition, there are some manufacturers that particularly outsource various operations to tap into sophisticated facilities and know-how, particularly if contract manufacturing firms are utilizing cutting-edge technologies, such as software-driven robotics, to enhance manufacturing processes and mitigate the risks and constraints associated with manual methods. With outsourcing becoming increasingly accepted as a viable and beneficial business model within this field, the global market for biologics contract manufacturing is expected to witness remarkable growth during the forecast period.

Key Market Insights

This report features an extensive study of the current market landscape, market size and future opportunities associated with the biologics contract manufacturing market, during the given forecast period. Further, the market report highlights the efforts of various stakeholders engaged in this rapidly emerging segment of the pharmaceutical industry. Key takeaways of the biologics contract manufacturing market are briefly discussed below.

Growing Demand for Biologics

Biologics are the essential structural analogs of various biomolecules found in the human body. They are highly specific and have fewer side effects as compared to conventional pharmacological molecules. Thus, biologics exhibit enormous potential to target and eradicate the cause of a disease at the genetic level, which has resulted in the increased interest of various stakeholders in the pharmaceutical and biotechnology industry. Additionally, novel modalities, including recombinant proteins, vaccines, cell and gene therapies, are growing faster than any other segment of medicine. This has led the biologics to be on the verge of surpassing small molecules in terms of revenues.

Fundamental Advancements in the Biopharmaceutical Manufacturing Processes

Conventional methods of biopharmaceutical manufacturing have been revolutionized by single-use technologies and its adoption is rapidly increasing for the production of biologics, including monoclonal antibodies, antibody drug conjugates, vaccines, cell and gene therapies. These disruptive innovations have also played a crucial role during the COVID-19 pandemic, facilitating rapid process development for manufacturing monoclonal antibodies-based drugs and vaccines. Closed plug-and-play solutions offered by single-use systems enable process intensification and continuous manufacturing, thereby becoming a preferred choice from developmental phases to commercial production of biologics.

Competitive Landscape of Biologics Contract Manufacturing Companies

The current landscape features the presence of over 305 biologics CMO offering contract manufacturing services for biologics. It is worth mentioning that there has been a substantial rise in the number of biologics manufacturing companies over the past decade, indicating a growing demand for capacities for manufacturing both novel and conventional drugs. Further, a significant proportion of the companies (30%) offer services for contract manufacturing of APIs and FDFs to biologic developers; notable examples include 3P Biopharmaceuticals, Afton Scientific, Baccinex, Celltrion, Eubiologics, Genovior, Hybio Pharmaceutical, Kanda BioTech, Lonza and Lubrizol Life Sciences.

Biologics Contract Manufacturing Market Size: North America to Hold the Largest Market Share

The global market for biologics contract manufacturing is estimated to be more than USD 19 billion in 2023. North America currently holds the largest share (34%) of the market, owing to the increasing R&D investments and number of clinical studies pertaining to the development of large molecules. Further, the biologics contract manufacturing market in Asia-Pacific is expected to grow at a relatively high CAGR of 11% during the forecast period. In terms of type of biologic manufactured, cell therapies capture around 40% share of the biologics contract manufacturing market by 2035.

Mammalian Cell Cultures is the Most Preferred Choice of Expression System Amongst Biologics Contract Manufacturing Players

Mammalian cell cultures have become the predominant expression system for the production of biopharmaceuticals, owing to their ability to effectively complete the post-translational modifications required for drug safety and efficacy. Over the past decade, the productivity of mammalian cell culture processes has grown dramatically due to improvements in cell line development.

Biologics CMO Made Considerable Investments to Build or Expand Manufacturing Facilities, With Some Global CMOs Re-evaluating Capacity Investments

The biologics CMO are actively adding new facilities in order to accommodate the growing biologics demand. These players are vigorously advancing their capabilities to serve as a fully integrated one-stop-shop by offering a range of biologic services, such as plasmid and viral vector development, fill-finish capabilities and gene delivery solutions. In order to expand the capabilities, expansion and investment in manufacturing facilities is essential. In June 2023, Enzene Biosciences announced the opening of its new state-of-the-art manufacturing facility in Pune, India with an aim to extend their drug development and manufacturing capabilities. In another announcement in March 2023, Biose expanded its live biotherapeutic product (LBP) process development and production capabilities with the opening of a new manufacturing facility in Massachusetts, US.

Post COVID-19 and considering the changes in macro-economic factors, some global biologics CMOs have recently re-evaluated their capacity expansions. In March 2023, Boehringer Ingelheim announced its plans to open a second biologics manufacturing facility in Austria is currently on hold.

Biologics Contract Manufacturing Market Trends Analysis: Increasing Partnerships and Collaborations to Foster Progress and Innovation

Stakeholders in the biopharmaceutical manufacturing industry have forged several partnerships in order to enhance their service portfolios. The growing preference for outsourcing bioprocessing operations is evident from the rise in partnership activity. It is worth highlighting that more than 61% of deals were inked in the last three years. Additionally, this segment of the global contract manufacturing market is growing rapidly and consistently after the COVID-19 pandemic. Notably, majority of the deals are focused on manufacturing and development of biologics, followed by mergers and acquisitions. This can be attributed to the incessant efforts of biologics CMO to further advance the development of their product offerings, across different phases. In May 2023, 3P Biopharmaceuticals signed an agreement with Zhittya Genesis Medicine to manufacture the latter company’s therapeutic candidate, for the treatment of neurodegenerative diseases (Parkinson’s disease). Further, in February 2023, AGC Biologics entered into an agreement with Genenta to manufacture cell therapy lentivirus-based product.

Leading CMOs Engaged in Biologics Contract Manufacturing Market

Examples of key biologics CMO (which have also been profiled in this market report) offering manufacturing services include (in alphabetical order) AGC Biologics, Boehringer Ingelheim, Catalent, Cell Therapies, Charles River Laboratories, FUJIFILM Diosynth Biotechnologies, KBI Biopharma, Kemwell Biopharma, Lonza, Miltenyi Biotec, Minaris Regenerative Medicine, Samsung Biologics, Sandoz, Vetter Pharma, WuXi Biologics. This market report includes an easily searchable excel database of all the biologics CMO and details on their manufacturing facilities worldwide.

Recent Developments in the Biologics Contract Manufacturing Market

Several recent developments have taken place in the global biologics contract manufacturing market. Some of these recent initiatives have been mentioned below. These developments, even if they took place post the release of this market report, substantiate the overall market trends that have been outlined in the analysis.

  • In June 2023, Cell and Gene Therapy Catapult announced a technology licensing agreement with Albumedix, under which the latter company’s latest technology will be utilized for improving the manufacturing of viral vectors.
  • In June 2023, Wuxi Biologics, offering end-to-end solutions to discover, develop and manufacture biologics, announced the expansion of its capacity for drug substances and drug products at its facility in Wuppertal, Germany.
  • In March 2023, Samsung Biologics announced the construction of a fifth plant, at its facility in Incheon, South Korea, as part of its strategic expansion in response to increased market demand. Upon its completion, the plant is expected to hold a manufacturing capacity of 180,000 L and will expand the company’s total site capacity to 784,000 L by investing a sum of KRW 1.9 trillion.
  • It is interesting to note that in February 2023, LOTTE BIOLOGICS announced the addition of three biomanufacturing plants in South Korea in order to produce a total of 360,000 L of antibody drugs. Such capacity additions are expected to drive biologics contract manufacturing market growth, during the forecast period.

Scope of the Report

The market report presents an in-depth analysis, highlighting the capabilities of various biologics CMO engaged in this industry, across different geographies. Amongst other elements, the market research report features:

  • A preface providing an introduction to the full market report, Biologics Contract Manufacturing Market, 2023-2035.
  • An outline of the systematic research methodology adopted to conduct the study on the biologics contract manufacturing market, providing insights on the various assumptions, methodologies, and quality control measures employed to ensure accuracy and reliability of the findings.
  • An overview of economic factors that impact the overall biologics contract manufacturing market, including historical trends, currency fluctuation, foreign exchange impact, recession, and inflation measurement.
  • An executive summary of the key insights captured during the research, offering a high-level view on the current state of the biologics contract manufacturing market and its likely evolution in the short to mid-to-long term.
  • A brief introduction to the biologics contract manufacturing market, highlighting general overview of biopharmaceuticals, biopharmaceutical manufacturing processes, and various expression systems used for the development of different types of biotherapeutic products. Further, it features a brief overview of biologics contract manufacturing, along with a detailed discussion on the need for outsourcing within the biopharmaceutical industry. It also provides information on the challenges faced by players currently engaged in this market.
  • An overview of the current market landscape of companies engaged in offering contract manufacturing services for biologics, including a detailed analysis based on several relevant parameters, such as year of establishment, company size (based on number of employees), location of headquarters, type of service offered (API and FDF manufacturing), type of biologic manufactured (antibody drug conjugates, antibodies, biosimilars, cell therapies, gene therapies, nucleic acids / oligonucleotides, plasmid DNA / viral vectors, proteins / peptides, vaccines and others), scale of operation (preclinical, clinical and commercial), type of expression system used (mammalian, microbial and others), type of bioreactor used (single-use and stainless steel) and mode of operation of bioreactor (batch, fed batch and continuous).
  • An insightful analysis, highlighting the detailed landscape of the biopharmaceutical manufacturing facilities established across the key geographical regions (North America, Europe, Asia-Pacific and Rest of the World), highlighting the manufacturing hubs for biologics.
  • Elaborate profiles of key biologics CMO based in North America that offer contract manufacturing services for biologics. Each profile features a brief overview of the company, along with details related to its biologic-related service portfolio, manufacturing facilities, recent developments, and an informed future outlook.
  • Elaborate profiles of key biologics CMO based in Europe that offer contract manufacturing services for biologics. Each profile features a brief overview of the company, along with details related to its biologic-related service portfolio, manufacturing facilities, recent developments, and an informed future outlook.
  • Elaborate profiles of key biologics CMO based in Asia-Pacific that offer contract manufacturing services for biologics. Each profile features a brief overview of the company, along with details related to its biologic-related service portfolio, manufacturing facilities, recent developments, and an informed future outlook.
  • A detailed discussion on the key enablers in this industry, including certain niche product classes, such as antibody drug conjugates (ADCs), bispecific antibodies, cell therapies, gene therapies and viral vectors, which are likely to have a significant impact on the growth of the contract services market.
  • A case study on the growing global biosimilars market, highlighting the associated opportunities for biologics CMOs and CDMOs.
  • A case study comparing the key characteristics of small and large molecule drugs, along with details on the various steps involved in their respective manufacturing processes.
  • A detailed discussion on the benefits and challenges associated with in-house manufacturing, featuring a brief overview of the various parameters that a drug / therapy developer may need to take into consideration while deciding whether to manufacture its products in-house or outsource the production operations.
  • A qualitative analysis, highlighting various factors that need to be taken into consideration by biopharmaceutical developers while deciding whether to manufacture their respective products in-house or engage the services of a biologics CMO.
  • A review of the various biopharmaceutical-focused manufacturing initiatives undertaken by top 12 big pharma players (shortlisted on the basis of 2022 revenues), highlighting trends across various parameters, such as number of initiatives, year of initiative, purpose of initiative, type of initiative, scale of operation and type of biologic manufactured.
  • An analysis of the recent collaborations within the biologics contract manufacturing market, based on several relevant parameters, such as year of partnership, type of partnership, type of biologic manufactured, therapeutic area, most active players (in terms of number of deals inked) and regional distribution of partnership activity that have taken place in this industry, during the period 2018-2023 (till July).
  • A detailed analysis of the various mergers and acquisitions that have taken place within this industry, during the period 2018-2023 (till July), based on several relevant parameters, such as year of agreement, type of deal, geographical location of companies, type of acquisition, type of biologic manufactured and key value drivers.
  • A detailed review of expansion initiatives undertaken by biologics CMO, during the period 2016-2023 (till July), along with information on several relevant parameters, such as year of expansion, purpose of expansion, type of biologic manufactured and location of expanded facility.
  • An analysis of the recent developments within the biologics contract manufacturing market, highlighting information on the funding investments made during the period 2016-2022 (till July), along with information on the technology advancements related to biomanufacturing.
  • An estimate of the overall installed capacity for the manufacturing of biopharmaceuticals, based on information reported by various industry stakeholders in the public domain, highlighting the distribution of the available capacity, based on size of manufacturer (small, mid-sized, and large and very large), type of expression system used (mammalian, microbial and others) and geography (North America, Europe, Asia-Pacific and Rest of the World).
  • An informed estimate of the annual demand for biologics, taking into account the top 20 biologics, based on various relevant parameters, such as target patient population, dosing frequency and dose strength of the abovementioned products.
  • A company size-wise, detailed analysis of the total cost of ownership for biologics CMO, during the period 2023-2043.
  • A discussion on affiliated trends, key drivers and challenges, under an elaborate SWOT analysis, which are likely to impact the industry’s evolution, including a Harvey ball analysis, highlighting the relative effect of each SWOT analysis on the overall biopharmaceutical industry.
  • A case study on the virtual business model concept, along with its role in the overall biopharmaceutical industry. It also features a discussion on the advantages and risks / challenges associated with outsourcing operations from virtual service providers.
  • An elaborate discussion on the future opportunities / trends within the biologics contract manufacturing market that are likely to influence the market growth of this industry over the forecast period.

One of the primary objectives of the presented market report is to conduct a comprehensive market forecast analysis, aiming to estimate both the current market size and the future opportunities within the biopharmaceutical contract manufacturing sector over the next decade. Drawing insights from various parameters, anticipated adoption trends, and validated through primary research, the report offers an informed estimate of the market's evolution throughout the forecast period from 2023 to 2035. It encompasses a detailed analysis of the likely distribution of current and projected opportunities within the biologics contract manufacturing market, considering various relevant factors. These factors include the type of service provided (API Manufacturing, FDF Manufacturing), the type of biologic manufactured (antibodies, cell therapies, vaccines, and other biologics), the expression system used (mammalian, microbial, and others), the scale of operation (preclinical/clinical and commercial), company size (small, mid-sized, large, and very large), key geographical regions (North America, Europe, Asia-Pacific, Middle East and North Africa, and Latin America), and key players in the industry. To enhance the robustness of the model and address future uncertainties associated with key parameters, the report offers three market forecast scenarios: conservative, base, and optimistic. These scenarios represent different trajectories of the industry's evolution.

The opinions and insights presented in the market report were influenced by discussions held with stakeholders in the industry. The report features detailed transcripts of interviews held with the following industry stakeholders:

  • Chief Executive Officer, Mid-Sized Company, Scotland
  • Chief Executive Officer and Co-Founder, Small Company, Slovenia
  • Chief Technical Officer, Large Company, USA
  • President and Chief Operating Officer, Mid-Sized Company, China
  • Senior Director of Global Strategic Marketing, Large Company, USA
  • Senior Director of Commercial Strategy and Market Insights, Large Company, USA
  • Global Head of Sales and Marketing and Head of Business Development, Large Company, USA
  • Business Development Manager, Small Company, Spain
  • Manager Marketing and Sales, Mid-Sized Company, Germany

All actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. Financial figures mentioned in this market report are in USD, unless otherwise specified.

Key Companies Profiled

  • AGC Biologics
  • Boehringer Ingelheim
  • Catalent
  • Cell Therapies
  • Charles River Laboratories
  • FUJIFILM Diosynth Biotechnologies
  • KBI Biopharma
  • Kemwell Biopharma
  • Lonza
  • Miltenyi Biotec
  • Minaris Regenerative Medicine
  • Samsung Biologics
  • Sandoz
  • Vetter Pharma
  • Wuxi Biologics

Table of Contents

1 PREFACE
1.1. Biopharmaceutical Contract Manufacturing Market Overview
1.2. Key Market Insights
1.3. Scope of the Report
1.4. Research Methodology
1.5. Key Questions Answered
1.6. Chapter Outlines
2 RESEARCH METHODOLOGY
2.1. Chapter Overview
2.2. Research Assumptions
2.3. Project Methodology
2.4. Forecast Methodology
2.5. Robust Quality Control
2.6. Key Market Segmentations
2.7. Key Considerations
2.7.1. Demographics
2.7.2. Economic Factors
2.7.3. Government Regulations
2.7.4. Supply Chain
2.7.5. COVID Impact / Related Factors
2.7.6. Market Access
2.7.7. Healthcare Policies
2.7.8. Industry Consolidation
3. ECONOMIC AND OTHER PROJECT SPECIFIC CONSIDERATIONS
3.1. Chapter Overview
3.2. Market Dynamics
3.2.1. Time Period
3.2.1.1. Historical Trends
3.2.1.2. Current and Forecasted Estimates
3.2.2. Currency Coverage
3.2.2.1. Overview of Major Currencies Affecting the Market
3.2.2.2. Impact of Currency Fluctuations on the Industry
3.2.3. Foreign Exchange Impact
3.2.3.1. Evaluation of Foreign Exchange Rates and Their Impact on Market
3.2.3.2. Strategies for Mitigating Foreign Exchange Risk
3.2.4. Recession
3.2.4.1. Historical Analysis of Past Recessions and Lessons Learnt
3.2.4.2. Assessment of Current Economic Conditions and Potential Impact on the Market
3.2.5. Inflation
3.2.5.1. Measurement and Analysis of Inflationary Pressures in the Economy
3.2.5.2. Potential Impact of Inflation on the Market Evolution
4 EXECUTIVE SUMMARY
5 INTRODUCTION
5.1. Chapter Overview
5.2. Overview of Biopharmaceuticals
5.3. Expression Systems for Biopharmaceuticals
5.3.1. Insect Expression Systems
5.3.2. Mammalian Expression Systems
5.3.3. Microbial Expression Systems
5.3.3.1. Bacterial Expression Systems
5.3.3.2. Fungal Expression Systems
5.3.3.3. Yeast Expression Systems
5.3.4. Plant Expression Systems
5.3.5. Mammalian versus Microbial Expression Systems
5.4. Manufacturing Process of Biopharmaceuticals
5.4.1. Upstream Processing
5.4.2. Fermentation
5.4.3. Downstream Processing
5.5. Overview of Contract Manufacturing
5.6. Need for Outsourcing Biopharmaceutical Manufacturing Operations
5.6.1. Commonly Outsourced Manufacturing Operations for Biopharmaceuticals
5.6.2. Advantages of Outsourcing Biopharmaceutical Manufacturing Operations
5.6.3. Risks and Challenges Associated with Outsourcing Biopharmaceutical Manufacturing Operations
5.7. Key Considerations While Selecting a Contract Manufacturing Partner
5.8. Future Perspectives
6 MARKET LANDSCAPE
6.1. Chapter Overview
6.2. Biopharmaceutical Contract Manufacturers: Overall Market Landscape
6.2.1. Analysis by Year of Establishment
6.2.2. Analysis by Company Size
6.2.3. Analysis by Location of Headquarters
6.2.4. Analysis by Type of Service Offered
6.2.5. Analysis by Type of Biologic Manufactured
6.2.6. Analysis by Scale of Operation
6.2.7. Analysis by Type of Expression System Used
6.2.8. Analysis by Type of Bioreactor Used
6.2.9. Analysis by Mode of Operation of Bioreactor
7 REGIONAL CAPABILITY ANALYSIS
7.1. Chapter Overview
7.2. Key Assumptions and Parameter
7.3. Overview of Biopharmaceutical Contract Manufacturing Facilities
7.3.1. Analysis by Type of Service Offered
7.3.2. Analysis by Scale of Operation
7.4. Regional Capability Analysis: Biopharmaceutical Contract Manufacturing Facilities in North America
7.5. Regional Capability Analysis: Biopharmaceutical Contract Manufacturing Facilities in Europe
7.6. Regional Capability Analysis: Biopharmaceutical Contract Manufacturing Facilities in Asia-Pacific
7.7. Regional Capability Analysis: Biopharmaceutical Contract Manufacturing Facilities in Rest of the World
8 BIOPHARMACEUTICAL CONTRACT MANUFACTURING IN NORTH AMERICA
8.1. Chapter Overview
8.2. Biopharmaceutical Contract Manufacturing in the US: Regulatory Scenario
8.3. Leading Biopharmaceutical CMOs in North America
8.3.1. AGC Biologics
8.3.1.1. Company Overview
8.3.1.2. Service Portfolio
8.3.1.2.1. Process Development
8.3.1.2.2. cGMP Manufacturing
8.3.1.2.3. Quality and Regulatory Services
8.3.1.2.4. Process Validation
8.3.1.3. Financial Information
8.3.1.4. Manufacturing Facilities
8.3.1.5. Recent Developments and Future Outlook
8.3.2. Catalent
8.3.2.1. Company Overview
8.3.2.2. Service Portfolio
8.3.2.2.1. Cell Line Development
8.3.2.2.2. Biomanufacturing
8.3.2.2.3. ADCs and Bioconjugates Manufacturing
8.3.2.2.4. Biosimilars Development and Manufacturing
8.3.2.2.5. Fill / Finish Solutions and Delivery Services
8.3.2.2.6. Analytical Services
8.3.2.3. Clinical Supply Services
8.3.2.4. Financial Information
8.3.2.5. Manufacturing Facilities
8.3.2.6. Recent Developments and Future Outlook
8.3.3. FUJIFILM Diosynth Biotechnologies
8.3.3.1. Company Overview
8.3.3.2. Service Portfolio
8.3.3.2.1. Strain Development
8.3.3.2.2. Process Development
8.3.3.2.3. cGMP Manufacturing
8.3.3.2.4. Analytical Solutions
8.3.3.3. Financial Information
8.3.3.4. Manufacturing Facilities
8.3.3.5. Recent Developments and Future Outlook
8.3.4. KBI Biopharma
8.3.4.1. Company Overview
8.3.4.2. Service Portfolio
8.3.4.2.1. Process Development
8.3.4.2.2. Analytical Development
8.3.4.2.3. GMP Manufacturing
8.3.4.2.4. Clinical Cell Therapy Support
8.3.4.3. Manufacturing Facilities
8.3.4.4. Recent Developments and Future Outlook
8.3.5. Charles River Laboratories
8.3.5.1 Company Overview
8.3.5.2. Service Portfolio
8.3.5.2.1. Cell Sourcing
8.3.5.2.2. Cell and Gene Therapy Solutions
8.3.5.2.3. Biologics Testing Solutions
8.3.5.2.4. Avian Vaccine Services
8.3.5.2.5. QC Microbial Solutions
8.3.5.2.6. Scientific and Regulatory Advisory Services
8.3.5.3. Financial Information
8.3.5.4. Manufacturing Facilities
8.3.5.5. Recent Developments and Future Outlook
8.4. Other Leading Biopharmaceutical CMOs in North America
8.4.1. Cytiva
8.4.1.1. Company Overview
8.4.2. Patheon
8.4.2.1. Company Overview
8.4.3 Piramal Pharma Solutions
8.4.3.1. Company Overview
9 BIOPHARMACEUTICAL CONTRACT MANUFACTURING IN EUROPE
9.1. Chapter Overview
9.2. Biopharmaceutical Contract Manufacturing in Europe: Regulatory Scenario
9.2.1. EMA’s cGMP Regulations
9.3. Leading Biopharmaceutical CMOs in Europe
9.3.1. Boehringer Ingelheim (BioXcellence)
9.3.1.1. Company Overview
9.3.1.2. Service Portfolio
9.3.1.2.1. Process Development
9.3.1.2.1.1. Expression Systems
9.3.1.2.1.2. Upstream Technology
9.3.1.2.1.3. Downstream Technology
9.3.1.2.1.4. Other Process Development Services
9.3.1.2.2. Quality Assurance
9.3.1.2.3. Fill / Finish Services
9.3.1.3. Financial Information
9.3.1.4. Manufacturing Facilities
9.3.1.5. Recent Developments and Future Outlook
9.3.2. Lonza
9.3.2.1. Company Overview
9.3.2.2. Service Portfolio
9.3.2.3. Manufacturing Services
9.3.2.4. Financial Information
9.3.2.5. Manufacturing Facilities
9.3.2.6. Recent Developments and Future Outlook
9.3.3. Sandoz
9.3.3.1. Company Overview
9.3.3.2. Service Portfolio
9.3.3.3. Financial Information
9.3.3.4. Manufacturing Facilities
9.3.3.5. Recent Developments and Future Outlook
9.3.4. Vetter Pharma
9.3.4.1. Company Overview
9.3.4.2. Service Portfolio
9.3.4.3. Manufacturing Facilities
9.3.4.4. Recent Developments and Future Outlook
9.3.5. Miltenyi Biotec
9.3.5.1. Company Overview
9.3.5.2. Service Portfolio
9.3.5.3. Manufacturing Facilities
9.3.5.4. Recent Developments and Future Outlook
9.4. Other Leading Biopharmaceutical CMOs in Europe
9.4.1 Novasep
9.4.1.1. Company Overview
9.4.2 Olon
9.4.2.1. Company Overview
9.4.3 Rentschler Biopharma
9.4.3.1. Company Overview
10 BIOPHARMACEUTICAL CONTRACT MANUFACTURING IN ASIA-PACIFIC AND REST OF THE WORLD
10.1. Chapter Overview
10.2. Biopharmaceutical Contract Manufacturing in China
10.2.1. Biopharmaceutical Contract Manufacturing in China: Regulatory Scenario
10.3. Leading Biopharmaceutical CMOs in China
10.3.1. WuXi Biologics
10.3.1.1. Company Overview
10.3.1.2. Service Portfolio
10.3.1.2.1. Discovery Services
10.3.1.2.2. Development Services
10.3.1.2.3. Testing Services
10.3.1.2.4. Clinical Manufacturing Services
10.3.1.3. Financial Information
10.3.1.4. Manufacturing Facilities
10.3.1.5. Recent Developments and Future Outlook
10.4. Biopharmaceutical Contract Manufacturing in India
10.4.1. Biopharmaceutical Contract Manufacturing in India: Regulatory Scenario
10.5. Leading Biopharmaceutical CMOs in India
10.5.1. Kemwell Biopharma
10.5.1.1. Company Overview
10.5.1.2. Service Portfolio
10.5.1.2.1. Development Services for Biopharmaceuticals
10.5.1.2.2. Manufacturing Services for Biopharmaceuticals
10.5.1.3. Manufacturing Facilities
10.5.1.4. Recent Developments and Future Outlook
10.6. Biopharmaceutical Contract Manufacturing in Japan
10.6.1. Biopharmaceutical Contract Manufacturing in Japan: Regulatory Scenario
10.7. Leading Biopharmaceutical CMOs in Japan
10.7.1. Minaris Regenerative Medicine
10.7.1.1. Company Overview
10.7.1.2. Service Portfolio
10.7.1.2.1. Manufacturing Development Services
10.7.1.2.2. GMP Manufacturing
10.7.1.3. Manufacturing Facilities
10.7.1.4. Recent Developments and Future Outlook
10.8. Biopharmaceutical Contract Manufacturing in South Korea
10.8.1. Biopharmaceutical Contract Manufacturing in South Korea: Regulatory Scenario
10.9. Leading Biopharmaceutical CMOs in South Korea
10.9.2. Samsung Biologics
10.9.2.1. Company Overview
10.9.2.2. Service Portfolio
10.9.2.2.1. Process Development
10.9.2.2.2. Analytical Services
10.9.2.2.3. cGMP Manufacturing Services
10.9.2.2.4. Aseptic Fill / Finish Services
10.9.2.2.5. Quality Services
10.9.2.3. Financial Information
10.9.2.4. Manufacturing Facilities
10.9.2.5. Recent Developments and Future Outlook
10.10. Biopharmaceutical Contract Manufacturing in Australia
10.10.1. Biopharmaceutical Contract Manufacturing in Australia: Regulatory Scenario
10.11. Leading Biopharmaceutical CMOs in Australia
10.11.1. Cell Therapies
10.11.1.1. Company Overview
10.11.1.2. Service Portfolio
10.11.1.3. Manufacturing Facilities
10.11.1.4. Recent Developments and Future Outlook
10.12. Other Leading Biopharmaceutical CMOs in Asia-Pacific and Rest of the World
10.12.1 AcuraBio (Formerly Known as Luina Bio)
10.12.1.1. Company Overview
10.12.2 Celltrion
10.12.2.1. Company Overview
10.12.3 Takara Bio
10.12.3.1. Company Overview
11 NICHE BIOPHARMACEUTICAL SECTORS
11.1. Chapter Overview
11.2. Bispecific Antibodies
11.2.1. Approved and Clinical Bispecific Antibody Therapeutics: Overall Market Landscape
11.2.2. Bispecific Antibodies: Pipeline Analysis
11.2.2.1. Analysis by Phase of Development
11.2.2.2. Analysis by Target Indication
11.2.3. Bispecific Antibody Therapeutics: Technology Platforms
11.2.4. Key Considerations for Manufacturing and Associated Challenges
11.2.5. Role of CMOs in Offering Services for Bispecific Antibodies
11.2.5.1. CMOs Offering Services for Bispecific Antibodies
11.3. Antibody Drug Conjugates (ADCs)
11.3.1. Components of ADCs
11.3.1.1. Antibody
11.3.1.2. Cytotoxin
11.3.1.3. Linker
11.3.2. Antibody Drug Conjugates (ADCs): Pipeline Analysis
11.3.2.1. Analysis by Status of Development
11.3.2.2. Analysis by Target Disease Indication
11.3.2.3. Most Active Players: Analysis by Number of Therapies
11.3.3. Antibody Drug Conjugate Developers
11.3.4. Manufacturing Process
11.4. Cell Therapies
11.4.5. Technical Challenges Related to Antibody Drug Conjugates Manufacturing
11.4.6. Role of CMOs in Offering Services for ADCs
11.4.6.1. CMOs Offering Services for ADCs
11.4.1. Cell Therapies: Overall Market Landscape
11.4.2. Overview of Cell Therapy Manufacturing
11.4.2.1. Cell Therapy Manufacturing Models
11.4.2.1.1. Centralized Manufacturing
11.4.2.1.2. Decentralized Manufacturing
11.4.3. Key Challenges for Manufacturing Cell Therapies
11.4.4. Key Factors Impacting Cell Therapy Manufacturing
11.4.4.1. Characterization
11.4.4.2. Cost of Goods
11.4.4.3. Automation of Cell Therapy Manufacturing
11.4.5 Cell Therapies: Pipeline Analysis
11.4.5.1 Analysis by Type of Cell Manufactured
11.4.6. Stem Cell Therapies: Analysis by Phase of Development
11.4.7. T-Cell Therapies: Analysis by Phase of Development
11.4.8. Role of CMOs in Offering Services for Cell Therapies
11.4.8.1. CMOs Offering Services for Cell Therapies
11.5. Gene Therapies
11.5.1. Gene Therapies: Pipeline Analysis
11.5.1.1. Analysis by Stage of Development
11.5.1.2. Analysis by Phase of Development
11.5.1.3. Analysis by Type of Vector Used
11.5.1.3.1. Clinical Pipeline
11.5.1.3.2. Preclinical Pipeline
11.5.1.4. Analysis by Therapeutic Area
11.5.1.4.1. Clinical and Commercial Pipeline
11.5.1.4.2. Preclinical Pipeline
11.5.2. Role of CMOs in Offering Services for Gene Therapies
11.5.2.1 CMOs Offering Services for Gene Therapies
11.6. Viral Vectors
11.6.1. Viral Vectors: Pipeline Analysis
11.6.1.1. Analysis by Location of Viral Vectors Manufacturing Facilities
11.6.1.2. Analysis by Type of Viral Vector Manufactured
11.6.2. Role of CMOs in Offering Services for Viral Vectors
11.6.2.1. CMOs Offering Services for Viral Vectors
11.7. Plasmid DNA
11.7.1. Plasmid DNA: Pipeline Analysis
11.7.1.1. Analysis by Location of Manufacturing Facilities
11.7.2. Role of CMOs in Offering Services for Plasmid DNA
11.7.2.1. CMOs Offering Services for Plasmid DNA
12 CASE STUDY: OUTSOURCING OF BIOSIMILARS
12.1. Chapter Overview
12.2. Overview of Biosimilars
12.3. Development Stages of Biosimilars
12.4. Regulatory Requirements for Licensing of Biosimilars
12.5. Need for Outsourcing Manufacturing Operations
12.6. Impact of Biosimilars on the Global Contract Manufacturing Market
12.6.1. Biosimilars: Historical Trend of FDA Approvals
12.7. Biosimilars Contract Manufacturing Service Providers
12.8. Challenges Associated with Outsourcing of Biosimilar Manufacturing Operations
13 CASE STUDY: COMPARISON OF SMALL AND LARGE MOLECULE DRUGS / THERAPIES
13.1. Chapter Overview
13.2. Small Molecule and Large Molecule Drugs / Therapies
13.2.1. Comparison of General Characteristics
13.2.2. Comparison of Key Specifications
13.2.3. Comparison of Manufacturing Process
13.2.4. Comparison of Key Manufacturing Challenges
14 CASE STUDY: IN-HOUSE MANUFACTURING
14.1. Chapter Overview
14.2. In-House Manufacturing
14.2.1. Benefits Associated with In-House Manufacturing
14.2.2. Risks Associated with In-House Manufacturing
14.3. Outsourcing Trends in the Biopharmaceutical Industry
14.3.1. Types of Outsourcing Partners
14.4. Manufacturing Approaches Used for Approved Biologics, 2016-2022
14.5. Choosing the Right Strategy: In-House Manufacturing versus Outsourcing
15 MAKE VERSUS BUY DECISION MAKING FRAMEWORK
15.1. Chapter Overview
15.2. Key Assumptions and Parameters
15.3. Biopharmaceutical Contract Manufacturers: Make versus Buy Decision Making
15.3.1. Scenario 1
15.3.2. Scenario 2
15.3.3. Scenario 3
15.3.4. Scenario 4
15.4. Conclusion
16 BIG PHARMA INITIATIVES
16.1. Chapter Overview
16.2. Biopharmaceutical Related Initiatives by Big Pharmaceutical Players
16.2.1. Analysis by Number of Initiatives
16.2.2. Analysis by Year of Initiative
16.2.3. Analysis by Purpose of Initiative
16.2.4. Analysis by Type of Initiative
16.2.4.1. Analysis by Type of Partnership
16.2.4.2. Analysis by Type of Expansion
16.2.5. Analysis by Scale of Operation
16.2.6. Analysis by Type of Biologic Manufactured
16.2.7. Analysis of Big Pharma Players by Year of Initiative
16.2.8. Analysis of Big Pharma Players by Purpose of Initiative
16.2.9. Analysis by Year and Type of Initiative
16.2.10. Analysis of Big Pharma Players by Region of Expansion
16.2.11. Analysis of Big Pharma Players by Type of Biologic Manufactured
17 PARTNERSHIPS AND COLLABORATIONS
17.1. Chapter Overview
17.2. Partnership Models
17.3. Biopharmaceutical Contract Manufacturing: Partnerships and Collaborations
17.3.1. Analysis by Year of Partnership
17.3.2. Analysis by Type of Partnership
17.3.3. Analysis by Year and Type of Partnership
17.3.4. Analysis by Type of Biologic Manufactured
17.3.5. Analysis by Year of Partnership and Type of Biologic Manufactured
17.3.6. Analysis by Type of Partnership and Type of Biologic Manufactured
17.3.7. Analysis by Scale of Operation
17.3.8. Analysis by Therapeutic Area
17.3.9. Most Active Players: Analysis by Number of Partnerships
17.3.10. Analysis by Geography
17.3.10.1. Local and International Agreements
17.3.10.2. Intracontinental and Intercontinental Agreements
18 MERGERS AND ACQUISITIONS
18.1. Chapter Overview
18.2. Merger and Acquisition Models
18.3. Biopharmaceutical Contract Manufacturing: Mergers and Acquisitions
18.3.1. Cumulative Year-wise Trend of Mergers and Acquisitions
18.3.2. Analysis by Type of Acquisition
18.3.3. Analysis by Geography
18.3.3.1. Local and International Mergers and Acquisitions
18.3.3.2. Intracontinental and Intercontinental Mergers and Acquisitions
18.3.3.3. Year-wise Trend in North America, Europe and Asia-Pacific
18.3.4 Most Active Acquirers: Analysis by Number of Acquisitions
18.3.5 Analysis by Key Value Drivers
18.3.6. Analysis by Year of Acquisition and Key Value Drivers
18.3.7. Analysis by Type of Biologic Manufactured
18.3.8. Analysis by Key Value Drivers and Type of Biologic Manufactured
18.4. Key Acquisitions: Deal Multiples
18.4.1. Year-wise Trend of Deal Multiple Amount
19 RECENT EXPANSIONS
19.1. Chapter Overview
19.2. Biopharmaceutical Contract Manufacturing: Recent Expansions
19.2.1. Analysis by Year of Expansion
19.2.2. Analysis by Purpose of Expansion
19.2.3. Analysis by Year and Purpose of Expansion
19.2.4. Analysis by Type of Biologic Manufactured
19.2.5. Analysis by Purpose of Expansion and Type of Biologic Manufactured
19.2.6. Analysis by Location of Expanded Facility
19.2.7. Most Active Players: Analysis by Number of Recent Expansions
19.2.8. Analysis by Purpose of Expansion and Location of Expanded Facility
19.2.9. Analysis by Amount Invested
19.2.10. Recent Expansions: 2016-2020 and 2021-2023 Scenario
20 RECENT DEVELOPMENTS
20.1. Chapter Overview
20.2. Types of Funding
20.3. Biopharmaceutical Contract Manufacturing: Funding and Investment Analysis
20.3.1. Analysis by Year of Funding
20.3.2. Analysis by Amount Invested
20.3.3. Analysis by Type of Funding
20.3.4. Analysis by Year and Type of Funding
20.3.5. Analysis of Funding Instances and Amount Invested by Geography (Continent)
20.3.6. Analysis of Funding Instances and Amount Invested by Geography (Country)
20.3.7. Most Active Players: Analysis by Number of Funding Instances
20.3.8. Most Active Players: Analysis by Total Amount Raised
20.3.9. Leading Investors: Analysis by Number of Funding Instances
20.3.10. Leading Investors: Analysis by Total Amount Raised
20.4. Technological Advancements
20.4.1. Single-Use Technology
20.4.2. Process Analytical Technology (PAT)
20.4.3. Continuous Processing
20.4.4. Quality by Design (QbD) in Bio-processing
20.4.5. Modular / Podular Biopharma Facilities
21 CAPACITY ANALYSIS
21.1. Chapter Overview
21.2. Key Assumptions and Methodology
21.3. Biopharmaceutical Contract Manufacturing: Global Installed Capacity
21.3.1. Analysis by Company Size
21.3.2. Analysis by Type of Expression System Used
21.3.3. Analysis by Geography
21.3.3.1. Analysis of Biopharmaceutical Contract Manufacturing Capacity in North America
21.3.3.2. Analysis of Biopharmaceutical Contract Manufacturing Capacity in Europe
21.3.3.3. Analysis of Biopharmaceutical Contract Manufacturing Capacity in Asia-Pacific
21.3.3.4. Analysis of Biopharmaceutical Contract Manufacturing Capacity in Rest of the World
21.4. Concluding Remarks
22 DEMAND ANALYSIS
22.1. Chapter Overview
22.2. Key Assumptions and Methodology
22.3. Global Demand for Biopharmaceuticals
22.4. Global Demand for Emerging Novel Biologics
22.4.1. Global Demand for ADC Therapeutics
22.4.2. Global Demand for Cell Therapy Manufacturing
23. TOTAL COST OF OWNERSHIP FOR BIOPHARMACEUTICAL CONTRACT MANUFACTURING ORGANIZATIONS
23.1. Chapter Overview
23.2. Key Parameters
23.3. Assumptions and Methodology
23.4. Total Cost of Ownership (Sample Dataset)
23.5. Total Cost of Ownership for Mid-sized Biopharmaceutical Contract Manufacturing Organizations, Y0-Y20
23.5.1. Total Cost of Ownership for Mid-sized Biopharmaceutical Contract Manufacturing Organizations: Analysis by CAPEX, Y0
23.5.2. Total Cost of Ownership for Mid-sized Biopharmaceutical Contract Manufacturing Organizations: Analysis by OPEX, Y1-Y20
23.7. Total Cost of Ownership for Large / Very Large Biopharmaceutical Contract Manufacturing Organizations, Y0-Y20
23.7.1. Total Cost of Ownership for Large / Very Large Biopharmaceutical Contract Manufacturing Organizations: Analysis by CAPEX, Y0
23.7.2. Total Cost of Ownership for Large / Very Large Biopharmaceutical Contract Manufacturing Organizations: Analysis by OPEX, Y1-Y20
24 GLOBAL BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET
24.1. Chapter Overview
24.2. Assumptions and Methodology
24.3. Global Biopharmaceutical Contract Manufacturing Market, Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
24.3.1. Scenario Analysis
24.3.1.1. Conservative Scenario
24.3.1.2. Optimistic Scenario
24.4. Key Market Segmentations
25 BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY TYPE OF SERVICE OFFERED
25.1. Chapter Overview
25.2. Key Assumptions and Methodology
25.3 Biopharmaceutical Contract Manufacturing Market: Distribution by Type of Service Offered, 2018, 2023 and 2035
25.3.1. API Manufacturing: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
25.3.2. FDF Manufacturing: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
25.4. Data Triangulation and Validation
26 BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY TYPE OF BIOLOGIC MANUFACTURED
26.1. Chapter Overview
26.2. Key Assumptions and Methodology
26.3 Biopharmaceutical Contract Manufacturing Market: Distribution by Type of Biologic Manufactured, 2018, 2023 and 2035
26.3.1. Antibodies: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
26.3.2. Cell Therapies: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
26.3.3. Vaccines: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
26.3.4. Other Biologics: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
26.4. Data Triangulation and Validation
27 BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY TYPE OF EXPRESSION SYSTEM USED
27.1. Chapter Overview
27.2. Key Assumptions and Methodology
27.3 Biopharmaceutical Contract Manufacturing Market: Distribution by Type of Expression System Used, 2018, 2023 and 2035
27.3.1. Mammalian Expression Systems: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
27.3.2. Microbial Expression Systems: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
27.3.3. Other Expression Systems: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
27.4. Data Triangulation and Validation
28 BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY SCALE OF OPERATION
28.1. Chapter Overview
28.2. Key Assumptions and Methodology
28.3. Biopharmaceutical Contract Manufacturing Market: Distribution by Scale of Operation, 2018, 2023 and 2035
28.3.1. Preclinical / Clinical Operations: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
28.3.2. Commercial Operations: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
28.4. Data Triangulation and Validation
29 BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY COMPANY SIZE
29.1. Chapter Overview
29.2. Key Assumptions and Methodology
29.3 Biopharmaceutical Contract Manufacturing Market: Distribution by Company Size, 2018, 2023 and 2035
29.3.1. Small Companies: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
29.3.2. Mid-sized Companies: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
29.3.3. Large and Very Large Companies: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
29.4. Data Triangulation and Validation
30 BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY GEOGRAPHY
30.1. Chapter Overview
30.2. Key Assumptions and Methodology
30.3 Biopharmaceutical Contract Manufacturing Market: Distribution by Geography, 2018, 2023 and 2035
30.3.1. North America: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
30.3.1.1. US: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
30.3.1.2. Canada: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
30.3.2. Europe: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
30.3.2.1. Italy: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
30.3.2.2. Germany: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
30.3.2.3. France: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
30.3.2.4. Spain: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
30.3.2.5. UK: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
30.3.2.6. Rest of Europe: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
30.3.3. Asia-Pacific: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
30.3.3.1. China: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
30.3.3.2. India: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
30.3.3.3. South Korea: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
30.3.3.4. Japan: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
30.3.3.5. Rest of Asia-Pacific: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
30.3.4. Latin America: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
30.3.5. Middle East and North Africa: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
30.8. Data Triangulation and Validation
31 BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY LEADING PLAYERS
31.1. Chapter Overview
31.2. Key Assumptions and Methodology
31.3 Biopharmaceutical Contract Manufacturing Market: Distribution by Leading Players
31.4. Data Triangulation and Validation
32 CASE STUDY: VIRTUAL PHARMACEUTICAL COMPANIES
32.1. Chapter Overview
32.2. Historical Evolution of the Virtual Business Model
32.3. Virtual Pharmaceutical Companies as a Subset of the Overall Biopharmaceutical Industry
32.4. Advantages Associated with Outsourcing Operations to Virtual Service Providers
32.5. Key Challenges Associated with Outsourcing Operations to Virtual Service Providers
33. SWOT ANALYSIS
33.1 Chapter Overview
33.2. Strengths
33.3. Weaknesses
33.4. Opportunities
33.5. Threats
33.6. Comparison of SWOT Factors
33.7. Conclusion
34 FUTURE OF THE BIOPHARMACEUTICAL CMO MARKET
34.1. Chapter Overview
34.2. Outsourcing Activities to Witness Significant Growth in the Coming Years
34.3. Shift from One-time Contracts to Strategic Partnerships
34.4. Integration / Adoption of New and Innovative Technologies
34.4.1. Single-use Bioreactors
34.4.2. Novel Bioprocess Techniques
34.4.3. Bioprocess Automation
34.5. Focus on Niche Therapeutic Areas
34.6. Growing Biosimilars Market to Contribute to the Growth of the Contract Services Segment
34.7. Capability Expansion by CMOs to become One-Stop-Shops
34.8. Offshoring Outsourcing Activities to Maximize Profits and Expand Existing Capacities
34.9. Increase in Financial Inflow and Outsourcing Budgets
34.10. Challenges Faced by Sponsors and Service Providers
34.10.1. Concerns Related to Single-use Systems
34.10.2. Issues Related to Capacity Fluctuations
34.11. Concluding Remarks
35 CONCLUSION
36 EXECUTIVE INSIGHTS
36.1. Chapter Overview
36.2. RoslinCT
36.2.1. Company Snapshot
36.2.2. Interview Transcript
36.3. Chapter Overview
36.3. JAFRAL Biosolutions
36.3.1. Company Snapshot
36.3.2. Interview Transcript
36.4. Chapter Overview
36.4. Discovery Life Sciences
36.4.1. Company Snapshot
36.4.2. Interview Transcript
36.5. Chapter Overview
36.5. Bioworkshops
36.5.1. Company Snapshot
36.5.2. Interview Transcript
36.6. Aldevron
36.6.1. Company Snapshot
36.6.2. Interview Transcript
36.7. Resilience
36.7.1. Company Snapshot
36.7.2. Interview Transcript
36.8. Minaris Regenerative Medicine
36.8.1. Company Snapshot
36.8.2. Interview Transcript
36.9. 53Biologics
36.9.1. Company Snapshot
36.9.2. Interview Transcript
36.10. Richter-Helm BioLogics
36.10.1. Company Snapshot
36.10.2. Interview Transcript
37 APPENDIX I: TABULATED DATA38 APPENDIX II: LIST OF COMPANIES AND ORGANIZATIONS39 APPENDIX III: DETAILS OF PARTNERSHIPS AND COLLABORATIONS
LIST OF FIGURES
Figure 2.1 Research Methodology: Project Methodology
Figure 2.2 Research Methodology: Forecast Methodology
Figure 2.3 Research Methodology: Robust Quality Control
Figure 2.4 Research Methodology: Key Market Segmentation
Figure 3.1 Lessons Learnt from Past Recessions
Figure 4.1 Executive Summary: Overall Market Landscape
Figure 4.2 Executive Summary: Regional Capability Analysis
Figure 4.3 Executive Summary: Partnerships and Collaborations
Figure 4.4 Executive Summary: Mergers and Acquisitions
Figure 4.5 Executive Summary: Recent Expansions
Figure 4.6 Executive Summary: Funding and Investment Analysis
Figure 4.7 Executive Summary: Demand Analysis
Figure 4.8 Executive Summary: Total Cost of Ownership
Figure 4.9 Executive Summary: Market Forecast and Opportunity Analysis
Figure 5.1 Types of Biopharmaceuticals
Figure 5.2 Types of Expression Systems Used for the Production of Biopharmaceuticals
Figure 5.3 Stages of the Biomanufacturing Process
Figure 5.4 Types of Third-Party Service Providers
Figure 5.5 Commonly Outsourced Biopharmaceutical Contract Manufacturing Operations
Figure 6.1 Biopharmaceutical Contract Manufacturers: Distribution by Year of Establishment
Figure 6.2 Biopharmaceutical Contract Manufacturers: Distribution by Company Size
Figure 6.3 Biopharmaceutical Contract Manufacturers: Distribution by Location of Headquarters (Region)
Figure 6.4 Biopharmaceutical Contract Manufacturers: Distribution by Location of Headquarters (Country)
Figure 6.5 Biopharmaceutical Contract Manufacturers: Distribution by Year of Establishment, Company Size and Location of Headquarters (Region) Figure 6.6 Biopharmaceutical Contract Manufacturers: Distribution by Type of Service Offered
Figure 6.7 Biopharmaceutical Contract Manufacturers: Distribution by Type of Biologic Manufactured
Figure 6.8 Biopharmaceutical Contract Manufacturers: Distribution by Type of Biologic Manufactured and Location of Headquarters (Region)
Figure 6.9 Biopharmaceutical Contract Manufacturers: Distribution by Type of Biologic Manufactured and Company Size
Figure 6.10 Biopharmaceutical Contract Manufacturers: Distribution by Scale of Operation
Figure 6.11 Biopharmaceutical Contract Manufacturers: Distribution by Type of Biologic Manufactured and Scale of Operation
Figure 6.12 Biopharmaceutical Contract Manufacturers: Distribution by Type of Expression System Used
Figure 6.13 Biopharmaceutical Contract Manufacturers: Distribution by Type of Expression System Used and Location of Headquarters (Region)
Figure 6.14 Biopharmaceutical Contract Manufacturers: Distribution by Type of Bioreactor Used
Figure 6.15 Biopharmaceutical Contract Manufacturers: Distribution by Mode of Operation of Bioreactor
Figure 7.1 Regional Distribution of Biopharmaceutical Contract Manufacturing Facilities
Figure 7.2 Biopharmaceutical Contract Manufacturing Facilities: Distribution by Type of Service Offered
Figure 7.3 Biopharmaceutical Contract Manufacturing Facilities: Distribution by Scale of Operation
Figure 7.4 Regional Capability Analysis: Biopharmaceutical Contract Manufacturing Facilities in North America
Figure 7.5 Regional Capability Analysis: Biopharmaceutical Contract Manufacturing Facilities in Europe
Figure 7.6 Regional Capability Analysis: Biopharmaceutical Contract Manufacturing Facilities in Asia-Pacific
Figure 7.7 Regional Capability Analysis: Biopharmaceutical Contract Manufacturing Facilities in Rest of the World
Figure 8.1 Biopharmaceutical Contract Manufacturing Industry: The US Market Scenario
Figure 8.2 Biopharmaceutical Contract Manufacturing in the US: Growth Drivers and Challenges
Figure 8.3 US FDA Guidelines: Elements of a Quality Agreement
Figure 8.4 US FDA Guidelines: Key Considerations for Biologic Manufacturing Operations
Figure 8.5 AGC Biologics: Annual Revenues, FY 2018-H1 FY 2023 (JPY Billion)
Figure 8.6 Catalent: Service Portfolio
Figure 8.7 Catalent: Biosimilars Service Portfolio
Figure 8.8 Catalent: Annual Revenues, FY 2018-FY 2023 (USD Billion)
Figure 8.9 FUJIFILM Diosynth Biotechnologies: Service Portfolio
Figure 8.10 FUJIFILM Diosynth Biotechnologies: Annual Revenues, FY 2018-FY 2022 (JPY Billion)
Figure 8.11 FUJIFILM Holdings: Annual Revenues by Business Divisions, FY 2022 (JPY Billion)
Figure 8.12 KBI Biopharma: Service Portfolio
Figure 8.13 Charles River Laboratories: Service Portfolio
Figure 8.14 Charles River Laboratories: Annual Revenues, FY 2018-H1 FY 2023 (USD Billion)
Figure 9.1 Biopharmaceutical Contract Manufacturing in Europe: Growth Drivers and Challenges
Figure 9.2 EMA GMP Guidelines: Key Considerations for the Contract Giver, Contract Acceptor and the Contract
Figure 9.3 Boehringer Ingelheim (BioXcellenece): Service Portfolio
Figure 9.4 Boehringer Ingelheim: Annual Revenues, FY 2018-H1 FY 2023 (EUR Billion)
Figure 9.5 Lonza: Service Portfolio
Figure 9.6 Lonza: Annual Revenues, FY 2018-H1 FY 2023 (CHF Billion)
Figure 9.7 Lonza: Annual Revenues by Business Divisions (CHF Billion)
Figure 9.8 Sandoz: Annual Revenues, FY 2018-H1 FY 2023 (USD Billion)
Figure 9.9 Vetter Pharma: Service Portfolio
Figure 10.1 Chinese Regulatory Guidelines: Key Considerations for the Contract Giver
Figure 10.2 Chinese Regulatory Guidelines: Key Considerations for the Contract Acceptor
Figure 10.3 Chinese Regulatory Guidelines: Key Aspects of the Contract
Figure 10.5 WuXi Biologics: Service Portfolio
Figure 10.6 Wuxi Biologics: Annual Revenues, FY 2018-H1 FY 2023 (RMB Billion)
Figure 10.7 Biopharmaceutical Contract Manufacturing in India: Growth Drivers
Figure 10.8 Kemwell Biopharma: Service Portfolio
Figure 10.9 Minaris Regenerative Medicine: Service Portfolio
Figure 10.10 Samsung Biologics: Service Portfolio
Figure 10.11 Samsung Biologics: Annual Revenues, FY 2018-H1 FY 2023 (KRW Billion)
Figure 10.12 Cell Therapies: Service Portfolio
Figure 11.1 Basic Structure of an Antibody
Figure 11.2 Approved and Clinical Bispecific Antibody Therapeutics: Distribution by Phase of Development
Figure 11.3 Approved and Clinical Bispecific Antibody Therapeutics: Distribution by Target Indication
Figure 11.4 Structure of an Antibody Drug Conjugate (ADC)
Figure 11.5 Antibody Drug Conjugates: Distribution by Status of Development
Figure 11.6 Antibody Drug Conjugates: Distribution by Target Disease Indication
Figure 11.7 Most Active Players: Distribution by Number of Therapies
Figure 11.8 Decentralized Manufacturing: Process Model
Figure 11.11 Cell Therapies: Challenges and Drivers
Figure 11.10 Cell Therapies: Potency as Critical Quality Attribute
Figure 11.11 Cell Therapy Manufacturing (Industry Players): Distribution by Type of Cell Manufactured
Figure 11.12 Cell Therapy Manufacturing (Industry Players): Distribution by Type of Immune Cell Manufactured
Figure 11.13 Cell Therapy Manufacturing (Industry Players): Distribution by Type of Stem Cell Manufactured
Figure 11.14 Stem Cell Therapies: Distribution by Phase of Development
Figure 11.15 T-Cell Therapies: Distribution by Phase of Development
Figure 11.16 Gene Therapies: Distribution by Stage of Development
Figure 11.17 Gene Therapies: Distribution by Phase of Development
Figure 11.18 Clinical and Commercial Pipeline of Gene Therapies: Distribution by Type of Vector Used
Figure 11.19 Early-stage Pipeline of Gene Therapies: Distribution by Type of Vector Used
Figure 11.20 Clinical and Commercial Pipeline of Gene Therapies: Distribution by Therapeutic Area
Figure 11.21 Early-Stage Pipeline of Gene Therapies: Distribution by Therapeutic Area
Figure 11.22 Viral Vector and Gene Therapy Manufacturers (Industry Players): Distribution by Location of Viral Vector Manufacturing Facilities (Continent-wise)
Figure 11.23 Vector and Gene Therapy Manufacturers (Non-Industry Players): Distribution by Type of Vector Manufactured
Figure 11.24 Plasmid DNA Manufacturers: Distribution by Location of Manufacturing Facility
Figure 12.1 Manufacturing Stages of a Biosimilar Product
Figure 12.2 Analytical and Functional Characterization Methods for Key Biosimilar Product
Figure 12.3 Regulatory Process Adopted for Licensing of a Biosimilar Product
Figure 12.4 Need for Outsourcing Biosimilar Manufacturing Operations
Figure 12.5 Biosimilars: Historical Trend of FDA Approvals, 2015-2022
Figure 12.6 Challenges Associated with Outsourcing Biosimilar Manufacturing Operations
Figure 13.1 Small Molecule and Large Molecule Drugs: Historical Trend of FDA Approval, 2005-2022
Figure 13.2 Small Molecules versus Large Molecules: Comparison of Manufacturing Process
Figure 14.1 Benefits Associated with In-House Manufacturing
Figure 14.2 Risks Associated with In-House Manufacturing
Figure 14.3 Advantages and Disadvantages of Different Types of Outsourcing Partnerships
Figure 15.1 Make versus Buy Decision Making Framework
Figure 15.2 Make versus Buy Decision Making Framework: Possible Scenarios
Figure 16.1 Big Pharma Initiatives: Distribution of Players by Number of Biopharmaceutical Contract Manufacturing Focused Initiatives
Figure 16.2 Big Pharma Initiatives: Cumulative Year-wise Trend, Pre-2005-2023
Figure 16.3 Big Pharma Initiatives: Distribution by Purpose of Initiative
Figure 16.4 Big Pharma Initiatives: Distribution by Type of Initiative
Figure 16.5 Big Pharma Initiatives: Distribution by Type of Partnership
Figure 16.6 Big Pharma Initiatives: Distribution by Type of Expansion
Figure 16.7 Big Pharma Initiatives: Distribution by Scale of Operation
Figure 16.8 Big Pharma Initiatives: Distribution by Type of Biologic Manufactured
Figure 16.9 Big Pharma Initiatives: Distribution of Players by Year and Number of Initiatives
Figure 16.10 Big Pharma Initiatives: Distribution of Players by Purpose of Initiative
Figure 16.11Big Pharma Initiatives: Distribution by Year and Type of Initiative
Figure 16.12Big Pharma Initiatives: Distribution of Players by Region of Expansion
Figure 16.13Big Pharma Initiatives: Distribution of Players by Type of Biologic Manufactured
Figure 17.1 Partnerships and Collaborations: Cumulative Year-wise Trend, 2019-2023
Figure 17.2 Partnerships and Collaborations: Distribution by Type of Partnership
Figure 17.3 Partnerships and Collaborations: Distribution by Year and Type of Partnership
Figure 17.4 Partnerships and Collaborations: Distribution by Type of Biologic Manufactured
Figure 17.5 Partnerships and Collaborations: Distribution by Year of Partnership and Type of Biologic Manufactured
Figure 17.6 Partnerships and Collaborations: Distribution by Type of Partnership and Type of Biologic Manufactured
Figure 17.7 Partnerships and Collaborations: Distribution by Scale of Operation
Figure 17.8 Partnerships and Collaborations: Distribution by Therapeutic Area
Figure 17.9 Most Active Players: Distribution by Number of Partnerships
Figure 17.10 Partnerships and Collaborations: Local and International Agreements
Figure 17.11 Partnerships and Collaborations: Intracontinental and Intercontinental Agreements
Figure 18.1 Mergers and Acquisitions: Year-Wise Cumulative Trend, 2015-2023
Figure 18.2 Mergers and Acquisitions: Distribution by Type of Acquisition
Figure 18.3 Local and International Mergers and Acquisitions
Figure 18.4 Intracontinental and Intercontinental Mergers and Acquisitions
Figure 18.5 Mergers and Acquisitions: Year-Wise Trend in North America, Europe and Asia-Pacific (2015-2023)
Figure 18.6 Most Active Acquirers: Distribution by Number of Acquisitions
Figure 18.7 Catalent Biologics: Information on Key Acquisitions
Figure 18.8 Mergers and Acquisitions: Distribution by Key Value Drivers
Figure 18.9 Mergers and Acquisitions: Distribution by Year of Acquisition and Key Value Drivers
Figure 18.10 Mergers and Acquisitions: Distribution by Type of Biologic Manufactured
Figure 18.11 Mergers and Acquisitions: Distribution by Key Value Drivers and Type of Biologic Manufactured
Figure 18.12 Mergers and Acquisitions: Year-Wise Trend of Deal Multiple Amount (USD Million)
Figure 19.1 Recent Expansions: Cumulative Year-wise Trend, 2016-2023
Figure 19.2 Recent Expansions: Distribution by Purpose of Expansion
Figure 19.3 Recent Expansions: Distribution by Year and Purpose of Expansion
Figure 19.4 Recent Expansions: Distribution by Type of Biologic Manufactured
Figure 19.5 Recent Expansions: Distribution by Purpose of Expansion and Type of Biologic Manufactured
Figure 19.6 Recent Expansions: Distribution by Location of Expanded Facility
Figure 19.7 Most Active Players: Distribution by Number of Recent Expansions
Figure 19.8 Recent Expansions: Distribution by Purpose of Expansion and Location of Expanded Facility
Figure 19.9 Recent Expansions: Distribution by Amount Invested (USD Million)
Figure 19.10 Recent Expansions: Regional Comparison 2016-2020 and 2021-2023 Scenario
Figure 20.1 Funding and Investment Analysis: Cumulative Year- wise Trend, 2016-2023
Figure 20.2 Funding and Investment Analysis: Cumulative Year- wise Trend by Amount Invested, 2016-2023 (USD Million)
Figure 20.3 Funding and Investment Analysis: Distribution of Funding Instances by Type of Funding
Figure 20.4 Funding and Investment Analysis: Distribution of Amount Invested by Type of Funding (USD Million)
Figure 20.5 Funding and Investment Analysis: Distribution by Year and Type of Funding
Figure 20.6 Funding and Investment Analysis: Distribution of Funding Instances and Total Amount Invested by Geography (Continent) (USD Million)
Figure 20.7 Funding and Investment Analysis: Distribution of Funding Instances and Total Amount Invested by Geography (Country) (USD Million)
Figure 20.8 Most Active Players: Distribution by Number of Funding Instances
Figure 20.9 Most Active Players: Distribution by Total Amount Raised (USD Million)
Figure 20.10 Leading Investors: Distribution by Number of Funding Instances
Figure 20.11 Leading Investors: Distribution by Amount Invested (USD Million)
Figure 21.1 Biopharmaceutical Contract Manufacturers: Global Production Capacity by Company Size
Figure 21.2 Biopharmaceutical Contract Manufacturers: Global Production Capacity by Type of Expression System Used
Figure 21.3 Biopharmaceutical Contract Manufacturers: Global Production Capacity by Location of Manufacturing Facilities
Figure 21.4 Biopharmaceutical Contract Manufacturing Capacity in North America
Figure 21.5 Biopharmaceutical Contract Manufacturing Capacity in Europe
Figure 21.6 Biopharmaceutical Contract Manufacturing Capacity in Asia-Pacific
Figure 21.8 Biopharmaceutical Contract Manufacturing Capacity in Rest of the World
Figure 22.1 Global Demand for Biopharmaceuticals, 2023-2035 (in kilograms)
Figure 22.2 Global Demand for ADC Therapeutics, 2023-2035 (in kilograms)
Figure 22.3 Global Demand for Cell Therapies, 2023-2035 (in terms of Number of Patients)
Figure 22.4 Global Demand for Cell Therapies, 2023-2035 (Billion Cells)
Figure 23.1 Total Cost of Ownership: Capital Expenditures (CAPEX)
Figure 23.2 Total Cost of Ownership: Operational Expenditures (OPEX)
Figure 23.3 Total Cost of Ownership for Mid-sized Biopharmaceutical Contract Manufacturing Organizations, Y0-Y20 (USD Million)
Figure 23.4 Total Cost of Ownership for Mid-sized Biopharmaceutical Contract Manufacturing Organizations, Y0: Distribution by CAPEX (USD Million)
Figure 23.5 Total Cost of Ownership for Mid-sized Biopharmaceutical Contract Manufacturing Organizations, Y1-Y20: Distribution by OPEX (USD Million)
Figure 23.6 Total Cost of Ownership for Large / Very Large Biopharmaceutical Contract Manufacturing Organizations, Y0-Y20 (USD Million)
Figure 23.7 Total Cost of Ownership for Large / Very Large Biopharmaceutical Contract Manufacturing Organizations, Y0: Distribution by CAPEX (USD Million)
Figure 23.8 Total Cost of Ownership for Large / Very Large Biopharmaceutical Contract Manufacturing Organizations, Y1-Y20: Distribution by OPEX (USD Million)
Figure 24.1 Global Biopharmaceutical Contract Manufacturing Market, Historical Trends (2018-2022)
Figure 24.2 Global Biopharmaceutical Contract Manufacturing Market, Forecasted Estimates (2023-2035), Base Scenario (USD Billion)
Figure 24.3 Global Biopharmaceutical Contract Manufacturing Market, Forecasted Estimates (2023-2035), Conservative Scenario (USD Billion)
Figure 24.4 Global Biopharmaceutical Contract Manufacturing Market, Forecasted Estimates (2023-2035), Optimistic Scenario (USD Billion)
Figure 25.1 Biopharmaceutical Contract Manufacturing Market: Distribution by Type of Service Offered, 2018, 2023 and 2035
Figure 25.2 Biopharmaceutical Contract Manufacturing Market for API Manufacturing, Historical Trends (2018-2022) and Forecasted Estimates (2023-2035) (USD Billion)
Figure 25.3 Biopharmaceutical Contract Manufacturing Market for FDF Manufacturing, Historical Trends (2018-2022) and Forecasted Estimates (2023-2035) (USD Billion)
Figure 26.1 Biopharmaceutical Contract Manufacturing Market: Distribution by Type of Biologic Manufactured, 2018, 2023 and 2035
Figure 26.2 Biopharmaceutical Contract Manufacturing Market for Antibodies, Historical Trends (2018-2022) and Forecasted Estimates (USD Billion)
Figure 26.3 Biopharmaceutical Contract Manufacturing Market for Cell Therapies, Historical Trends (2018-2022) and Forecasted Estimates (2023-2035) (USD Billion)
Figure 26.4 Biopharmaceutical Contract Manufacturing Market for Vaccines, Historical Trends (2018-2022) and Forecasted Estimates (2023-2035) (USD Billion)
Figure 27.1 Biopharmaceutical Contract Manufacturing Market: Distribution by Type of Expression System Used, 2018, 2023 and 2035
Figure 27.2 Biopharmaceutical Contract Manufacturing Market for Mammalian Expression Systems, Historical Trends (2018-2022) and Forecasted Estimates (2023-2035) (USD Billion)
Figure 27.3 Biopharmaceutical Contract Manufacturing Market for Microbial Expression Systems, Historical Trends (2018-2022) and Forecasted Estimates (2023-2035) (USD Billion)
Figure 27.4 Biopharmaceutical Contract Manufacturing Market for Other Expression Systems, Historical Trends (2018-2022) and Forecasted Estimates (2023-2035) (USD Billion)
Figure 28.1 Biopharmaceutical Contract Manufacturing Market: Distribution by Scale of Operation, 2018, 2023 and 2035
Figure 28.2 Biopharmaceutical Contract Manufacturing Market for Preclinical / Clinical Operations, Historical Trends (2018-2022) and Forecasted Estimates (2023-2035) (USD Billion)
Figure 28.3 Biopharmaceutical Contract Manufacturing Market for Commercial Operations, Historical Trends (2018-2022) and Forecasted Estimates (2023-2035) (USD Billion)
Figure 29.1 Biopharmaceutical Contract Manufacturing Market: Distribution by Company Size, 2018, 2023 and 2035
Figure 29.2 Biopharmaceutical Contract Manufacturing Market for Small Companies, Historical Trends (2018-2022) and Forecasted Estimates (2023-2035) (USD Billion)
Figure 29.3 Biopharmaceutical Contract Manufacturing Market for Mid- sized Companies, Historical Trends (2018-2022) and Forecasted Estimates (2023-2035) (USD Billion)
Figure 29.4 Biopharmaceutical Contract Manufacturing Market for Large and Very Large Companies, Historical Trends (2018-2022) and Forecasted Estimates (2023-2035) (USD Billion)
Figure 30.1 Biopharmaceutical Contract Manufacturing Market: Distribution by Geography, 2018, 2023 and 2035
Figure 30.2 Biopharmaceutical Contract Manufacturing Market in North America, Historical Trends (2018-2022) and Forecasted Estimates (2023-2035) (USD Billion)
Figure 30.3 Biopharmaceutical Contract Manufacturing Market in the US, Historical Trends (2018-2022) and Forecasted Estimates (2023-2035) (USD Billion)
Figure 30.4 Biopharmaceutical Contract Manufacturing Market in Canada, Historical Trends (2018-2022) and Forecasted Estimates (2023-2035) (USD Billion)
Figure 30.5 Biopharmaceutical Contract Manufacturing Market in Europe, Historical Trends (2018-2022) and Forecasted Estimates (2023-2035) (USD Billion)
Figure 30.6 Biopharmaceutical Contract Manufacturing Market in Italy, Historical Trends (2018-2022) and Forecasted Estimates (2023-2035) (USD Billion)
Figure 30.7 Biopharmaceutical Contract Manufacturing Market in Germany, Historical Trends (2018-2022) and Forecasted Estimates (2023-2035) (USD Billion)
Figure 30.8 Biopharmaceutical Contract Manufacturing Market in France, Historical Trends (2018-2022) and Forecasted Estimates (2023-2035) (USD Billion)
Figure 30.9 Biopharmaceutical Contract Manufacturing Market in Spain, Historical Trends (2018-2022) and Forecasted Estimates (2023-2035) (USD Billion)
Figure 30.10 Biopharmaceutical Contract Manufacturing Market in the UK, Historical Trends (2018-2022) and Forecasted Estimates (2023-2035) (USD Billion)
Figure 30.11 Biopharmaceutical Contract Manufacturing Market in Rest of Europe, Historical Trends (2018-2022) and Forecasted Estimates (2023-2035) (USD Billion)
Figure 30.12 Biopharmaceutical Contract Manufacturing Market in Asia- Pacific, Historical Trends (2018-2022) and Forecasted Estimates (2023-2035) (USD Billion)
Figure 30.13 Biopharmaceutical Contract Manufacturing Market in China, Historical Trends (2018-2022) and Forecasted Estimates (2023-2035) (USD Billion)
Figure 30.14 Biopharmaceutical Contract Manufacturing Market in India, Historical Trends (2018-2022) and Forecasted Estimates (2023-2035) (USD Billion)
Figure 30.15 Biopharmaceutical Contract Manufacturing Market in South Korea, Historical Trends (2018-2022) and Forecasted Estimates (2023-2035) (USD Billion)
Figure 30.16 Biopharmaceutical Contract Manufacturing Market in Japan, Historical Trends (2018-2022) and Forecasted Estimates (2023-2035) (USD Billion)
Figure 30.17 Biopharmaceutical Contract Manufacturing Market in Rest of Asia-Pacific, Historical Trends (2018-2022) and Forecasted Estimates (2023-2035) (USD Billion)
Figure 30.18 Biopharmaceutical Contract Manufacturing Market in Latin America, Historical Trends (2018-2022) and Forecasted Estimates (2023-2035) (USD Billion)
Figure 30.19 Biopharmaceutical Contract Manufacturing Market in Middle East and North Africa, Historical Trends (2018-2022) and Forecasted Estimates (2023-2035) (USD Billion)
Figure 30.20 Biopharmaceutical Contract Manufacturing Market:Distribution by Leading Players (USD Billion)
Figure 31.1 Overall Share of Virtual Biopharmaceutical Companies in the Biopharmaceutical Market (USD Billion)
Figure 31.2 Overall Share of Virtual Biopharmaceutical Companies in the Biopharmaceutical Contract Manufacturing Market in 2023 (USD Billion)
Figure 32.1 Biopharmaceutical Contract Manufacturing: SWOT Analysis
Figure 32.2 Global Biopharmaceuticals Market: Distribution of Number of FDA Approvals by Year, 2005-2022
Figure 32.3 Comparison of SWOT Factors: Harvey Ball Analysis
Figure 35.1 Concluding Remarks: Overall Market Landscape
Figure 35.2 Concluding Remarks: Partnerships and Collaborations
Figure 35.3 Concluding Remarks: Mergers and Acquisitions
Figure 35.4 Concluding Remarks: Funding and Investments
Figure 35.5 Concluding Remarks: Recent Expansions
Figure 35.6 Concluding Remarks: Capacity Analysis
Figure 35.7 Concluding Remarks: Demand Analysis
Figure 35.8 Concluding Remarks: Market Forecast and Opportunity Analysis (I/II)
Figure 35.9 Concluding Remarks: Market Forecast and Opportunity Analysis (II/II)
LIST OF TABLES
Table 5.1 Mammalian versus Microbial Expression Systems
Table 6.1 List of Biopharmaceutical Contract Manufacturers
Table 6.2 Biopharmaceutical Contract Manufacturers: Information on Type of Service Offered
Table 6.3 Biopharmaceutical Contract Manufacturers: Information on Type of Biologic Manufactured
Table 6.6 Biopharmaceutical Contract Manufacturers: Information on Scale of Operation
Table 6.5 Biopharmaceutical Contract Manufacturers: Information on Type of Expression System Used
Table 6.6 Biopharmaceutical Contract Manufacturers: Information on Type of Bioreactor Used
Table 6.7 Biopharmaceutical Contract Manufacturers: Information on Mode of Operation of Bioreactor
Table 7.1 List of Biopharmaceutical Contract Manufacturing Facilities in North America
Table 7.2 List of Biopharmaceutical Contract Manufacturing Facilities in Europe
Table 7.3 List of Biopharmaceutical Contract Manufacturing Facilities in Asia-Pacific
Table 7.4 List of Biopharmaceutical Contract Manufacturing Facilities in Rest of the World
Table 8.1 AGC Biologics: Company Overview
Table 8.2 AGC Biologics: Biologics Manufacturing Facilities
Table 8.3 AGC Biologics: Recent Developments and Future Outlook
Table 8.4 Catalent: Company Overview
Table 8.5 Catalent: Biologics Manufacturing Facilities
Table 8.6 Catalent: Recent Developments and Future Outlook
Table 8.7 FUJIFILM Diosynth Biotechnologies: Company Overview
Table 8.8 FUJIFILM Diosynth Biotechnologies: Biologics Manufacturing Facilities
Table 8.9 FUJIFILM Diosynth Biotechnologies: Recent Developments and Future Outlook
Table 8.10 KBI Biopharma: Company Overview
Table 8.11 KBI Biopharma: Biologics Manufacturing Facilities
Table 8.12 KBI Biopharma: Recent Developments and Future Outlook
Table 8.13 Charles River Laboratories: Company Overview
Table 8.14 Charles River Laboratories: Biologics Manufacturing Facilities
Table 8.15 Charles River Laboratories: Recent Developments and Future Outlook
Table 8.16 Cytiva: Company Overview
Table 8.17 Patheon: Company Overview
Table 8.18 Piramal Pharma Solutions: Company Overview
Table 9.1 FDA Quality Agreements and EMA cGMP Regulations: A Comparative Analysis
Table 9.2 Boehringer Ingelheim: Company Overview
Table 9.3 Boehringer Ingelheim: Biologics Manufacturing Facilities
Table 9.4 Boehringer Ingelheim: Recent Developments and Future Outlook
Table 9.5 Lonza: Company Overview
Table 9.6 Lonza: Biologics Manufacturing Facilities
Table 9.7 Lonza: Recent Developments and Future Outlook
Table 9.8 Sandoz: Company Overview
Table 9.9 Sandoz: Biologics Manufacturing Facilities
Table 9.10 Sandoz: Recent Developments and Future Outlook
Table 9.11 Vetter Pharma: Company Overview
Table 9.12 Vetter Pharma: Biologics Manufacturing Facilities
Table 9.13 Vetter Pharma: Recent Developments and Future Outlook
Table 9.14 Miltenyi Biotec: Company Overview
Table 9.15 Miltenyi Biotec: Biologics Manufacturing Facilities
Table 9.16 Miltenyi Biotec: Recent Developments and Future Outlook
Table 9.17 Novasep: Company Overview
Table 9.18 Olon: Company Overview
Table 9.19 Rentschler Biopharma: Company Overview
Table 10.1 WuXi Biologics: Company Overview
Table 10.2 Wuxi Biologics: Biologics Manufacturing Facilities
Table 10.3 WuXi Biologics: Recent Developments and Future Outlook
Table 10.4 Kemwell Biopharma: Company Overview
Table 10.5 Kemwell Biopharma: Recent Developments and Future Outlook
Table 10.6 Minaris Regenerative Medicine: Company Overview
Table 10.7 Minaris Regenerative Medicine: Biologics Manufacturing Facilities
Table 10.8 Minaris Regenerative Medicine: Recent Developments and Future Outlook
Table 10.9 Samsung BioLogics: Company Overview
Table 10.10 Samsung BioLogics: Biologics Manufacturing Facilities
Table 10.11 Samsung BioLogics: Recent Developments and Future Outlook
Table 10.12 Cell Therapies: Company Overview
Table 10.13 Cell Therapies: Recent Developments and Future Outlook
Table 10.14 AcuraBio: Company Overview
Table 10.15 Celltrion: Company Overview
Table 10.16 Takara Bio: Company Overview
Table 11.1 Bispecific Antibody Therapeutics: Information on Drug Candidate, Developer, Phase of Development and Target Antigen
Table 11.2 Bispecific Antibody Therapeutics: Information on Clinical Drug Candidates, Target Indications, Therapeutic Areas and Disease Segment
Table 11.3 Bispecific Antibody Therapeutics: List of Technology Platforms
Table 11.4 Bispecific Antibody Contract Manufacturers: List of Companies
Table 11.5 Commonly Used Cytotoxins for ADC Therapeutics
Table 11.6 Occupational Exposure Limit Bands, Safebridge Consultants
Table 11.7 Antibody Drug Conjugates: Information on Drug Candidates, Developers, Status of Development, Target Disease Indications and Therapeutic Areas
Table 11.8 Antibody Drug Conjugate Developers: Information on Year of Establishment, Company Size and Location of Headquarters
Table 11.9 ADC Contract Manufacturers: List of Companies
Table 11.10 Cell-based Therapies: Applications
Table 11.11 Cell-based Therapies: Commercialized Products,
Table 11.12 Key Cell Therapy Manufacturing Steps
Table 11.13 Advantages and Disadvantages of Centralized and Decentralized Manufacturing Models
Table 11.14 Cell Therapy Manufacturing (Industry Players): Information on Type of Cell Manufactured
Table 11.15 Cell Therapy Contract Manufacturers: List of Companies
Table 11.16 Gene Therapy Contract Manufacturers: List of Companies
Table 11.17 Vector and Gene Therapy Manufacturers (Non-Industry players): Information on Type of Vector Manufactured
Table 11.18 Viral Vectors Contract Manufacturers: List of Companies
Table 11.19 Plasmid DNA Manufacturing Service Providers: Information on Location of Manufacturing Facility
Table 11.20 Plasmid DNA Contract Manufacturers: List of Companies
Table 12.1 List of Biosimilars Contract Manufacturing Service Providers
Table 13.1 Small Molecules and Large Molecules: Strengths and Weaknesses
Table 13.2 Small Molecules and Large Molecules: Comparison of Key Characteristics
Table 13.3 Small Molecules and Large Molecules: Comparison of Development Characteristics
Table 14.1 List of FDA Approved Biologics (2016-2022)
Table 16.1 Big Pharma Initiatives: List of Biopharmaceutical Manufacturing Initiatives
Table 17.1 Biopharmaceutical Contract Manufacturing: List of Partnerships and Collaborations, 2019-2023
Table 17.2 Partnerships and Collaborations: Information on Type of Biologic Manufactured
Table 18.1 Biopharmaceutical Contract Manufacturing: List of Mergers and Acquisitions, 2015-2023
Table 18.2 Mergers and Acquisitions: Information on Key Value Drivers and Type of Biologic Manufactured
Table 18.3 Mergers and Acquisitions: Information on Deal Multiples, 2015-2023
Table 19.1 Biopharmaceutical Contract Manufacturing: List of Recent Expansions, 2016-2023
Table 20.1 Biopharmaceutical Contract Manufacturing: List of Funding and Investments, 2016-2023
Table 20.2 Funding and Investment Analysis: Summary of Investments
Table 20.3 Funding and Investment Analysis: Summary of Venture Capital Funding
Table 21.1 Biopharmaceutical Contract Manufacturers: Information on Capacity (Sample Data Set)
Table 21.2 Capacity Analysis: Average Capacity per Category (Sample Data Set)
Table 21.3 Capacity Analysis: Average Capacity for Mammalian Expression Systems (Sample Data Set)
Table 21.4 Capacity Analysis: Average Capacity for Microbial Expression Systems (Sample Data Set)
Table 21.5 Capacity Analysis: Average Capacity for Other Expression Systems (Sample Data Set)
Table 21.6 Capacity Analysis: Global Production Capacity
Table 22.1 Annual Biomanufacturing Capacity, 2023-2035 (Million Liters)
Table 23.1 Total Cost of Ownership: Sample Dataset for Mid-sized Companies
Table 23.2 Total Cost of Ownership: Sample Dataset for Large / Very Large Companies
Table 31.1 List of Leading Biopharmaceutical Contract Manufacturing Companies
Table 32.1 List of Virtual Biopharmaceutical Companies
Table 36.1 RoslinCT: Key Highlights
Table 36.2 Jafral Biosolutions: Key Highlights
Table 36.3 Discovery Life Sciences: Key Highlights
Table 36.4 Bioworkshops: Key Highlights
Table 36.5 Aldevron: Key Highlights
Table 36.6 Resilience: Key Highlights
Table 36.7 Minaris Regenerative Medicine: Key Highlights
Table 36.8 53Biologics: Key Highlights
Table 36.9 Richter-Helm BioLogics: Key Highlights
Table 37.1 Biopharmaceutical Contract Manufacturers: Distribution by Year of Establishment
Table 37.2 Biopharmaceutical Contract Manufacturers: Distribution by Company Size
Table 37.3 Biopharmaceutical Contract Manufacturers: Distribution by Location of Headquarters (Region)
Table 37.4 Biopharmaceutical Contract Manufacturers: Distribution by Location of Headquarters (Country)
Table 37.5 Biopharmaceutical Contract Manufacturers: Distribution by Year of Establishment, Company Size and Location of Headquarters (Region)
Table 37.6 Biopharmaceutical Contract Manufacturers: Distribution by Type of Service Offered
Table 37.7 Biopharmaceutical Contract Manufacturers: Distribution by Type of Biologic Manufactured
Table 37.8 Biopharmaceutical Contract Manufacturers: Distribution by Type of Biologic Manufactured and Location of Headquarters (Region)
Table 37.9 Biopharmaceutical Contract Manufacturers: Distribution by Type of Biologic Manufactured and Company Size
Table 37.10 Biopharmaceutical Contract Manufacturers: Distribution by Scale of Operation
Table 37.11 Biopharmaceutical Contract Manufacturers: Distribution by Type of Biologic Manufactured and Scale of Operation
Table 37.12 Biopharmaceutical Contract Manufacturers: Distribution by Type of Expression System Used
Table 37.13 Biopharmaceutical Contract Manufacturers: Distribution by Type of Expression System Used and Location of Headquarters (Region)
Table 37.14 Biopharmaceutical Contract Manufacturers: Distribution by Type of Bioreactor Used
Table 37.15 Biopharmaceutical Contract Manufacturers: Distribution by Mode of Operation of Bioreactor
Table 37.16 Regional Distribution of Biopharmaceutical Contract Manufacturing Facilities
Table 37.17 Biopharmaceutical Contract Manufacturing Facilities: Distribution by Type of Service Offered
Table 37.18 Biopharmaceutical Contract Manufacturing Facilities: Distribution by Scale of Operation
Table 37.19 AGC Biologics: Annual Revenues, FY 2018-H1 FY 2023 (JPY Billion)
Table 37.20 Catalent: Annual Revenues, FY 2018-FY 2023 (USD Billion)
Table 37.21 FUJIFILM Diosynth Biotechnologies: Annual Revenues, FY 2018-FY 2022 (JPY Billion)
Table 37.22 FUJIFILM Holdings: Annual Revenues by Business Divisions FY 2022 (JPY Billion)
Table 37.23 Charles River Laboratories: Annual Revenues, FY 2018- H1 FY 2023 (USD Billion)
Table 37.24 Boehringer Ingelheim: Annual Revenues, FY 2018- H1 FY 2023 (EUR Billion)
Table 37.25 Lonza: Annual Revenues, FY 2018-H1 FY 2023 (CHF Billion)
Table 37.26 Lonza: Annual Revenues by Business Divisions (CHF Billion)
Table 37.27 Sandoz: Annual Revenues, FY 2018-H1 FY 2023 (USD Billion)
Table 37.28 Wuxi Biologics: Annual Revenues, FY 2018-H1 FY 2023 (RMB Billion)
Table 37.29 Samsung Biologics: Annual Revenues, FY 2018-H1 FY 2023 (KRW Billion)
Table 37.30 Approved and Clinical Bispecific Antibody Therapeutics: Distribution by Phase of Development
Table 37.31 Approved and Clinical Bispecific Antibody Therapeutics: Distribution by Target Indications
Table 37.32 Antibody Drug Conjugates: Distribution by Status of Development
Table 37.33 Antibody Drug Conjugates: Distribution by Target Disease Indication
Table 37.34 Most Active Players: Distribution by Number of Therapies
Table 37.35 Cell Therapy Manufacturing (Industry Players): Distribution by Type of Cell Manufactured
Table 37.36 Cell Therapy Manufacturing (Industry Players): Distribution by Type of Immune Cell Manufactured
Table 37.37 Cell Therapy Manufacturing (Industry Players): Distribution by Type of Stem Cell Manufactured
Table 37.38 Stem Cell Therapies: Distribution by Phase of Development
Table 37.39 T-Cell Therapies: Distribution by Phase of Development
Table 37.40 Gene Therapies: Distribution by Stage of Development
Table 37.41 Gene Therapies: Distribution by Phase of Development
Table 37.42 Clinical and Commercial Pipeline of Gene Therapies: Distribution by Type of Vector Used
Table 37.43 Early-stage Pipeline of Gene Therapies: Distribution by Type of Vector Used
Table 37.44 Clinical and Commercial Pipeline of Gene Therapies: Distribution by Therapeutic Area
Table 37.45 Early-Stage Pipeline of Gene Therapies: Distribution by Therapeutic Area
Table 37.46 Viral Vector and Gene Therapy Manufacturers (Industry Players): Distribution by Location of Viral Vector Manufacturing Facilities (Continent)
Table 37.47 Vector and Gene Therapy Manufacturers (Non-Industry Players): Distribution by Type of Vector Manufactured
Table 37.48 Plasmid DNA Manufacturers: Distribution by Location of Manufacturing Facility
Table 37.49 Biosimilars: Historical Trend of FDA Approval, 2015-2022
Table 37.50 Small Molecule and Large Molecule Drugs: Historical Trend of FDA Approval, 2005-2022
Table 37.51 Big Pharma Initiatives: Distribution of Players by Number of Biopharmaceutical Contract Manufacturing Focused Initiatives
Table 37.52 Big Pharma Initiatives: Cumulative Year-wise Trend, Pre-2005-2023
Table 37.53 Big Pharma Initiatives: Distribution by Purpose of Initiative
Table 37.54 Big Pharma Initiatives: Distribution by Type of Initiative
Table 37.55 Big Pharma Initiatives: Distribution by Type of Partnership
Table 37.56 Big Pharma Initiatives: Distribution by Type of Expansion
Table 37.57 Big Pharma Initiatives: Distribution by Scale of Operation
Table 37.58 Big Pharma Initiatives: Distribution by Type of Biologic Manufactured
Table 37.59 Big Pharma Initiatives: Distribution of Players by Purpose of Initiative
Table 37.60 Big Pharma Initiatives: Distribution by Year and Type of Initiative
Table 37.61 Big Pharma Initiatives: Distribution of Players by Region of Expansion
Table 37.62 Partnerships and Collaborations: Cumulative Year-wise Trend, 2019-2023
Table 37.63 Partnerships and Collaborations: Distribution by Type of Partnership
Table 37.64 Partnerships and Collaborations: Distribution by Year and Type of Partnership
Table 37.65 Partnerships and Collaborations: Distribution by Type of Biologic Manufactured
Table 37.66 Partnerships and Collaborations: Distribution by Year of Partnership and Type of Biologic Manufactured
Table 37.67 Partnerships and Collaborations: Distribution by Type of Biologic Manufactured and Geography
Table 37.68 Partnerships and Collaborations: Distribution by Type of Partnership and Type of Biologic Manufactured
Table 37.69 Partnerships and Collaborations: Distribution by Scale of Operation
Table 37.70 Partnerships and Collaborations: Distribution by Therapeutic Area
Table 37.71 Most Active Players: Distribution by Number of Partnerships
Table 37.72 Partnerships and Collaborations: Local and International Agreements
Table 37.73 Partnerships and Collaborations: Intracontinental and Intercontinental Agreements
Table 37.74 Mergers and Acquisitions: Year-Wise Cumulative Trend, 2015-2023
Table 37.75 Mergers and Acquisitions: Distribution by Type of Agreement
Table 37.76 Mergers and Acquisitions: Intracontinental and Intercontinental Agreements
Table 37.77 Mergers and Acquisitions: Local and International Agreements
Table 37.78 Mergers and Acquisitions: Year-Wise Trend in North America, Europe and Asia- Pacific (2015-2023)
Table 37.79 Most Active Acquirers: Distribution by Number of Acquisitions
Table 37.80 Mergers and Acquisitions: Distribution by Key Value Drivers
Table 37.81 Mergers and Acquisitions: Distribution by Year of Acquisition and Key Value Drivers
Table 37.82 Mergers and Acquisitions: Distribution by Type of Biologic Manufactured
Table 37.83 Mergers and Acquisitions: Distribution by Key Value Drivers and Type of Biologic Manufactured
Table 37.84 Mergers and Acquisitions: Year-Wise Trend of Deal Multiple Amount (USD Million)
Table 37.85 Recent Expansions: Cumulative Year-wise Trend, 2016-2023
Table 37.86 Recent Expansions: Distribution by Purpose of Expansion
Table 37.87 Recent Expansions: Distribution by Year and Purpose of Expansion
Table 37.88 Recent Expansions: Distribution by Type of Biologic Manufactured
Table 37.89 Recent Expansions: Distribution by Purpose of Expansion and Type of Biologic Manufactured
Table 37.90 Recent Expansions: Distribution by Location of Expanded Facility
Table 37.91 Most Active Players: Distribution by Number of Recent Expansions
Table 37.92 Recent Expansions: Distribution by Purpose of Expansion and Location of Expanded Facility
Table 37.93 Recent Expansions: Distribution by Amount Invested (USD Million)
Table 37.94 Funding and Investment Analysis: Cumulative Year- wise Trend of Number of Funding Instances, 2016-2023
Table 37.95 Funding and Investment Analysis: Cumulative Year- wise Trend of Total Amount Invested, 2016-2023 (USD Million)
Table 37.96 Funding and Investment Analysis: Distribution of Number of Funding Instances by Type of Funding
Table 37.97 Funding and Investment Analysis: Distribution of Total Amount Invested by Type of Funding (USD Million)
Table 37.98 Funding and Investment Analysis: Distribution by Year and Type of Funding
Table 37.99 Funding and Investment Analysis: Distribution of Funding Instances and Total Amount Invested by Geography (Continent) (USD Million)
Table 37.100 Funding and Investment Analysis: Distribution of Funding Instances and Total Amount Invested by Geography (Country) (USD Million)
Table 37.101 Most Active Players: Distribution by Number of Funding Instances
Table 37.102 Most Active Players: Distribution by Total Amount Raised (USD Million)
Table 37.103 Leading Investors: Distribution by Number of Funding Instances
Table 37.104 Leading Investors: Distribution by Total Amount Invested (USD Million)
Table 37.105 Biopharmaceutical Contract Manufacturers: Global Production Capacity by Company Size
Table 37.106 Biopharmaceutical Contract Manufacturers: Global Production Capacity by Type of Expression System Used
Table 37.107 Biopharmaceutical Contract Manufacturers: Global Production Capacity by Location of Manufacturing Facilities
Table 37.108 Biopharmaceutical Contract Manufacturing Capacity in North America
Table 37.109 Biopharmaceutical Contract Manufacturing Capacity in Europe
Table 37.110 Biopharmaceutical Contract Manufacturing Capacity in Asia-Pacific
Table 37.111 Capacity Analysis: Biopharmaceutical Contract Manufacturing Capacity in Rest of the World
Table 37.112 Global Demand for Biopharmaceuticals, 2023-2235 (in kilograms)
Table 37.113 Global Demand for ADC Therapeutics, 2023-2035 (in kilograms)
Table 37.114 Global Demand for Cell Therapies, 2023-2035 (in terms of Number of Patients)
Table 37.115 Global Demand for Cell Therapies, 2023-2035 (Billion Cells)
Table 37.116 Total Cost of Ownership for Mid-sized Biopharmaceutical Contract Manufacturing Organizations, Y0-Y20 (USD Million)
Table 37.117 Total Cost of Ownership for Mid-sized Biopharmaceutical Contract Manufacturing Organizations, Y0: Distribution by CAPEX (USD Million)
Table 37.118 Total Cost of Ownership for Mid-sized Biopharmaceutical Contract Manufacturing Organizations, Y1-Y20: Distribution by OPEX (USD Million)
Table 37.119 Total Cost of Ownership for Large / Very Large Biopharmaceutical Contract Manufacturing Organizations, Y0-Y20 (USD Million)
Table 37.120 Total Cost of Ownership for Large / Very Large Biopharmaceutical Contract Manufacturing Organizations, Y0: Distribution by CAPEX (USD Million)
Table 37.121 Total Cost of Ownership for Large / Very Large Biopharmaceutical Contract Manufacturing Organizations, Y1-Y20: Distribution by OPEX (USD Million)
Table 37.122 Global Biopharmaceutical Contract Manufacturing Market, Historical Trends (2018-2022) and Forecasted Estimates (2023-2035) (USD Billion)
Table 37.123 Biopharmaceutical Contract Manufacturing Market: Distribution by Type of Service Offered, 2018, 2023 and 2035 (USD Billion)
Table 37.124 Biopharmaceutical Contract Manufacturing Market for API Manufacturing, Historical Trends (2018-2022) and Forecasted Estimates (2023-2035) (USD Billion)
Table 37.125 Biopharmaceutical Contract Manufacturing Market for FDF Manufacturing, Historical Trends (2018-2022) and Forecasted Estimates (2023-2035) (USD Billion)
Table 37.126 Biopharmaceutical Contract Manufacturing Market: Distribution by Type of Biologic Manufactured, 2018, 2023 and 2035 (USD Billion)
Table 37.127 Biopharmaceutical Contract Manufacturing Market for Antibodies, Historical Trends (2018-2022) and Forecasted Estimates (2023-2035) (USD Billion)
Table 37.128 Biopharmaceutical Contract Manufacturing Market for Cell Therapies, Historical Trends (2018-2022) and Forecasted Estimates (2023-2035) (USD Billion)
Table 37.129 Biopharmaceutical Contract Manufacturing Market for Vaccines, Historical Trends (2018-2022) and Forecasted Estimates (2023-2035) (USD Billion)
Table 37.130 Biopharmaceutical Contract Manufacturing Market for Other Biologics, Historical Trends (2018-2022) and Forecasted Estimates (2023-2035) (USD Billion)
Table 37.131 Biopharmaceutical Contract Manufacturing Market: Distribution by Type of Expression System Used, 2018, 2023 and 2035 (USD Billion)
Table 37.132 Biopharmaceutical Contract Manufacturing Market for Mammalian Expression Systems, Historical Trends (2018-2022) and Forecasted Estimates (2023-2035) (USD Billion)
Table 37.133 Biopharmaceutical Contract Manufacturing Market for Microbial Expression Systems, Historical Trends (2018-2022) and Forecasted Estimates (2023-2035) (USD Billion)
Table 37.134 Biopharmaceutical Contract Manufacturing Market for Other Expression Systems, Historical Trends (2018-2022) and Forecasted Estimates (2023-2035) (USD Billion)
Table 37.135 Biopharmaceutical Contract Manufacturing Market: Distribution by Scale of Operation, 2018, 2023 and 2035 (USD Billion)
Table 37.137 Biopharmaceutical Contract Manufacturing Market for Preclinical / Clinical Operations, Historical Trends (2018-2022) and Forecasted Estimates (2023-2035) (USD Billion)
Table 37.137 Biopharmaceutical Contract Manufacturing Market for Commercial Operations, Historical Trends (2018-2022) and Forecasted Estimates (2023-2035) (USD Billion)
Table 37.138 Biopharmaceutical Contract Manufacturing Market: Distribution by Company Size, 2018, 2023 and 2035 (USD Billion)
Table 37.139 Biopharmaceutical Contract Manufacturing Market for Small Companies, Historical Trends (2018-2022) and Forecasted Estimates (2023-2035) (USD Billion)
Table 37.140 Biopharmaceutical Contract Manufacturing Market for Mid- sized Companies, Historical Trends (2018-2022) and Forecasted Estimates (2023-2035) (USD Billion)
Table 37.141 Biopharmaceutical Contract Manufacturing Market for Large and Very Large Companies, Historical Trends (2018-2022) and Forecasted Estimates (2023-2035) (USD Billion)
Table 37.142 Biopharmaceutical Contract Manufacturing Market: Distribution by Key Geographical Regions, 2018, 2023 and 2035 (USD Billion)
Table 37.143 Biopharmaceutical Contract Manufacturing Market in North America, Historical Trends (2018-2022) and Forecasted Estimates (2023-2035) (USD Billion)
Table 37.144 Biopharmaceutical Contract Manufacturing Market in the US, Historical Trends (2018-2022) and Forecasted Estimates (2023-2035) (USD Billion)
Table 37.145 Biopharmaceutical Contract Manufacturing Market in Canada, Historical Trends (2018-2022) and Forecasted Estimates (2023-2035) (USD Billion)
Table 37.146 Biopharmaceutical Contract Manufacturing Market in Europe, Historical Trends (2018-2022) and Forecasted Estimates (2023-2035) (USD Billion)
Table 37.147 Biopharmaceutical Contract Manufacturing Market in Italy, Historical Trends (2018-2022) and Forecasted Estimates (2023-2035) (USD Billion)
Table 37.148 Biopharmaceutical Contract Manufacturing Market in Germany, Historical Trends (2018-2022) and Forecasted Estimates (2023-2035) (USD Billion)
Table 37.149 Biopharmaceutical Contract Manufacturing Market in France, Historical Trends (2018-2022) and Forecasted Estimates (2023-2035) (USD Billion)
Table 37.150 Biopharmaceutical Contract Manufacturing Market in Spain, Historical Trends (2018-2022) and Forecasted Estimates (2023-2035) (USD Billion)
Table 37.151 Biopharmaceutical Contract Manufacturing Market in the UK, Historical Trends (2018-2022) and Forecasted Estimates (2023-2035) (USD Billion)
Table 37.152 Biopharmaceutical Contract Manufacturing Market in Rest of Europe, Historical Trends (2018-2022) and Forecasted Estimates (2023-2035) (USD Billion)
Table 37.153 Biopharmaceutical Contract Manufacturing Market in Asia- Pacific, Historical Trends (2018-2022) and Forecasted Estimates (2023-2035) (USD Billion)
Table 37.154 Biopharmaceutical Contract Manufacturing Market in China, Historical Trends (2018-2022) and Forecasted Estimates (2023-2035) (USD Billion)
Table 37.155 Biopharmaceutical Contract Manufacturing Market in India, Historical Trends (2018-2022) and Forecasted Estimates (2023-2035) (USD Billion)
Table 37.156 Biopharmaceutical Contract Manufacturing Market in South Korea, Historical Trends (2018-2022) and Forecasted Estimates (2023-2035) (USD Billion)
Table 37.157 Biopharmaceutical Contract Manufacturing Market in Japan, Historical Trends (2018-2022) and Forecasted Estimates (2023-2035) (USD Billion)
Table 37.158 Biopharmaceutical Contract Manufacturing Market in Rest of Asia-Pacific, Historical Trends (2018-2022) and Forecasted Estimates (2023-2035) (USD Billion)
Table 37.159 Biopharmaceutical Contract Manufacturing Market in Middle East and North Africa, Historical Trends (2018-2022) and Forecasted Estimates (2023-2035) (USD Billion)
Table 37.160 Biopharmaceutical Contract Manufacturing Market in Latin America, Historical Trends (2018-2022) and Forecasted Estimates (2023-2035) (USD Billion)
Table 37.161 Biopharmaceutical Contract Manufacturing Market: Distribution by Leading Players (USD Billion)
Table 31.162 Overall Share of Virtual Biopharmaceutical Companies in the Biopharmaceutical Contract Manufacturing Market in 2023 (USD Billion)
Table 37.163 Global Biopharmaceuticals Market: Distribution of Number of FDA Approvals by Year, 2005-2023
Table 39.1 Biopharmaceutical Contract Manufacturing: List of Partnerships and Collaborations, 2015-2018

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

  • 20Med Therapeutics
  • 3P Biopharmaceuticals
  • 3SBio
  • 4D Pharma
  • 4TEEN4 Pharmaceuticals
  • 53Biologics
  • Aalto Scientific
  • AavantiBio
  • AB2 Bio
  • AbbVie
  • Abcam
  • AbCellera
  • Abeona Therapeutics
  • ABL Bio
  • AbMax Biotechnology
  • Abogen Biosciences
  • Abpro
  • Abzena
  • AC Immune
  • Acasti Pharma 
  • Accelerated Biosciences
  • Accellta
  • Accinov
  • ACES Pharma
  • Achilles Therapeutics 
  • ACT Therapeutics
  • Acticor Biotech 
  • AcuraBio (formerly Luina Bio)
  • Adagene
  • AdAlta
  • Adaptimmune
  • AdaptVac 
  • Adare Pharma Solutions (formerly Aptalis Pharmatech)
  • Adimmune
  • Adimmune 
  • ADL BioPharma
  • Advanced BioScience Laboratories
  • Advanced Biotherapeutics Consulting
  • Advanced Cell Technology and Engineering
  • Advaxia Biologics
  • Advaxis
  • Advent Bioservices 
  • Advent International
  • Affibody
  • Affinita Biotech
  • Affinity Life Sciences
  • Afton Scientific
  • AGC Biologics
  • Agilis Biotherapeutics
  • Airway Therapeutics
  • Ajinomoto Bio-Pharma Services
  • Akouos
  • Akron Biotech
  • Akshaya Bio
  • Alaunos (formerly Ziopharm Oncology)
  • Albumedix
  • Alcami
  • Alco Therapeutics
  • Aldevron
  • Alexion
  • Alira Health
  • AllCells
  • Allele Biotechnology and Pharmaceuticals
  • Allergy Therapeutics 
  • Allevi 
  • Alligator Bioscience
  • Almac
  • Almirall
  • Alpine Immune Sciences
  • Alteogen
  • Altheia Science
  • Altimmune
  • Altor Bioscience
  • Altruist Biologics
  • AM-Pharma
  • Amaran Biotechnology
  • Amatsigroup (Acquired by Eurofins)
  • AmbioPharma
  • Amgen
  • Ampersand Capital Partners
  • Andelyn Biosciences
  • Andes Biotechnologies
  • Ankarys Therapeutics HebeCell
  • ANL Bio
  • Antabio
  • Anthony Nolan
  • Anthos Therapeutics
  • apceth Biopharma
  • Applied StemCell
  • Aptevo Therapeutics
  • AR BROWN
  • Araris Biotech
  • Aravive Biologics
  • ARCALIS
  • Arcellx
  • Arch Biopartners
  • ArchiMed
  • ArcticZymes Technologies
  • Arcturus Therapeutics
  • Arcus Biosciences
  • Arecor 
  • Argenx
  • Arranta Bio (Acquired by Recipharm)
  • Aruvant Sciences
  • Asahi Kasei
  • ASC Therapeutics
  • Ascend Gene & Cell Therapies
  • Asher Biotherapeutics
  • Asimov
  • Asklepios BioPharmaceutical
  • ASLAN Pharmaceuticals
  • Aspire Health Science
  • Astero Bio
  • Astorg
  • AstraZeneca
  • Asymchem
  • Atara Biotherapeutics
  • Athenex
  • Athersys
  • aTyr Pharma
  • Aumgene Biosciences
  • Aurinia Pharmaceuticals
  • Austrianova
  • AutekBio
  • Autolomous
  • Autolus Therapeutics
  • Avectas
  • AveXis
  • Avid Bioservices
  • Avril Biopharma
  • Axcelead Drug Discovery Partners
  • Axcellerate Pharma
  • Axovant Gene Therapies
  • Babraham Bioscience Technologies
  • Baccinex 
  • Bachem 
  • Bacthera
  • Batavia Biosciences
  • Battelle
  • Bavarian Nordic
  • Baxter
  • Baxter BioPharma Solutions
  • Bayer
  • Baylor College of Medicine
  • Baylor Institute for Immunology Research
  • Baylor Scott & White Research Institute
  • BBI Solutions
  • BCN Peptides 
  • Beam Therapeutics 
  • BeiGene
  • Beijing Hetang Shenghua Medical Technology
  • Beijing Kawin Technology Share-Holding
  • Bennu Biotherapeutics
  • Berkeley Lights
  • BeRNA Therapeutics
  • Bexion Pharmaceuticals 
  • Bhami Research Laboratory
  • Bharat Biotech
  • BIA Separations
  • BianoGMP
  • BIBITEC
  • BiBo Pharma
  • BINEX
  • Bio Elpida
  • Bio Farma
  • Bio Immunitas
  • Bio-Ess Laboratories
  • Bio-Synthesis
  • Bioasis
  • BioCell
  • BioCentriq
  • BioCina
  • Biocon 
  • BioConnection
  • Biodextris
  • Biofabri
  • Biogen
  • Bioingenium
  • BioInno Bioscience
  • Bioinova 
  • BioInvent International
  • Biological E.
  • BioMARC
  • Biomay
  • BioMeca
  • Biomedical Advanced Research and Development Authority (BARDA)
  • BiondVax Pharmaceuticals
  • Bionova Scientific
  • BioNTech
  • Biopharma Global
  • Bioqube Ventures
  • Biosana Pharma
  • BioSciencesCorp
  • Biose Industrie
  • BioSig Technologies
  • Biosynth
  • BioTechnique
  • Biotechpharma UAB
  • BioTime
  • BioVaxys Technology
  • BIOVECTRA
  • Bioverativ
  • Biovian
  • Bioworkshops
  • BioXcellence
  • BioXpress Therapeutics
  • BJ Bioscience
  • BJP Laboratories
  • Bliss Biopharmaceutical
  • Bloom Science
  • bluebird bio
  • BlueJay Therapeutics
  • Boehringer Ingelheim
  • Boostimmune
  • Bora Pharmaceuticals
  • Boston Children’s Hospital
  • Boston Institute of Biotechnology
  • Boway Biotech Joint Antibody Engineering Technology Display and Service Center (a     part of Thermo Fisher Scientific)
  • Boyalife
  • BPL Biologics
  • BrainEver
  • BrainStorm Cell Therapeutics
  • Brammer Bio
  • Brenus Pharma
  • BriaCell Therapeutics
  • Bright Peak Therapeutics
  • Bristol Myers Squibb
  • Bryllan
  • BSP Pharmaceuticals
  • Burrard Pharmaceuticals
  • Buzzard Pharmaceuticals AB
  • C3i
  • Caeregen Therapeutics
  • Caisson Biotech
  • Caladrius Biosciences
  • California Institute for Regenerative Medicine (CIRM)
  • Calviri
  • Calypso Biotec
  • CANbridge Pharmaceuticals
  • Cancer Research Technology
  • Cancer Research UK (University of Southampton)
  • Canton Biologics
  • CanVirex
  • Capricor Therapeutics
  • Captozyme
  • CARBOGEN AMCIS
  • CaroGen
  • Catalent
  • Catamaran Bio
  • CDR-Life
  • Cedar Pharmaceuticals
  • Ceidos
  • Cell and Gene Therapy Catapult
  • Cell Culture Company
  • Cell One Partners
  • Cell Therapies
  • Cell-Easy
  • Cellab
  • Celladon 
  • Cellectis 
  • Cellenion
  • CellGenix
  • Cellin Technologies
  • CELLINK
  • Cellipoint Bioservices (Formerly Performance Cell Manufacturing)
  • Celltrion
  • CelluGen Biotech
  • Cellular Biomedicine Group
  • Cellular Therapeutics
  • Cellusion
  • CellVax Therapeutics
  • CellVec
  • Celonic
  • Celsion
  • Cenexi
  • Centaur Biopharmaceutical
  • Center for Breakthrough Medicines
  • Center for Innovation in Advanced Development and Manufacturing
  • Centers for Disease Control and Prevention 
  • Centre for Process Innovation
  • CEPiA (Commercial & External Partnership, Industrial Affairs)
  • Cerbios-Pharma
  • Cerium Pharmaceuticals
  • CEVEC Pharmaceuticals 
  • Changchun High-tech
  • Charles River Laboratories
  • Cheerland Biotechnology
  • Chemomab Therapeutics
  • ChemPartner
  • Children's Hospital of Philadelphia (CHOP)
  • Chime Biologics
  • Chimeron Bio
  • China Regenerative Medicine International (CRMI)
  • CHINAGENE
  • Chinese Peptide Company
  • Chiome Bioscience
  • CHO Pharma
  • Chong Kun Dang
  • Chord Therapeutics
  • Chr. Hansen
  • CiMaas
  • Cipla
  • CiRA Foundation 
  • Citryll
  • Clean Biologics
  • Clean Cells
  • CMAB Biopharma
  • CMC Biologics
  • CMIC 
  • Coalition for Epidemic Preparedness Innovations(CEPI)
  • Coave Therapeutics
  • Cobra Biologics
  • Codagenix
  • Cognate BioServices
  • Coherus BioSciences
  • CoJourney
  • Columbia University
  • CombiGene 
  • Comprehensive Cell Solutions (CCS)
  • Context Therapeutics
  • Cook MyoSite
  • CordenPharma
  • Coretherapix
  • CPC Scientific
  • CPI
  • CR Pharmaceutical
  • CRC for Cell Therapy Manufacturing
  • Creative Biogene
  • Creative Biolabs
  • CRISPR Therapeutics
  • Cryoport
  • CSBio
  • CSL Seqirus
  • CureCell
  • CureVac
  • Curia
  • CyanVac
  • Cytiva
  • CytoDyn
  • CytoSen Therapeutics 
  • Cytovance Biologics
  • CyTuVax
  • CZ Vaccines
  • DAAN Biotherapeutics
  • Daiichi Sankyo
  • Dalton Pharma Services
  • Danaher
  • DanausGT Biotechnology
  • DanDrit Biotech
  • DaTaMabs
  • Decibel Therapeutics
  • Decipher Biosciences
  • Delphi Genetics
  • Denali Therapeutics 
  • Dendreon
  • Dendreon Pharmaceuticals
  • DeoBioSciences
  • Department of Defense
  • DiNAMIQS
  • DiNAQOR 
  • DNDi
  • Dongkook Pharmaceutical
  • Dyadic International
  • Dyax 
  • Educell
  • Eikonoklastes Therapeutics
  • EirGenix
  • Eisai
  • Eli Lilly
  • Emendo Biotherapeutics
  • Emercell
  • Emergent BioSolutions
  • Emerson
  • ENCell
  • Encure Biopharma
  • Enimmune
  • Enleofen Bio 
  • Enterobiome
  • Enzene Biosciences
  • Enzolytics
  • ERC Belgium
  • ERS Genomics
  • Erytech Pharma
  • Esco Aster
  • Etinpro
  • EuBiologics
  • EUCODIS Bioscience
  • EUFETS 
  • EUROAPI
  • Eurocine Vaccines
  • Eurofins
  • Eurogentec 
  • Evanoa Bioscience
  • EVER Pharma
  • evitria
  • Evologic Technologies
  • Evotec
  • EXCELLGENE
  • Excellos
  • ExCellThera
  • Exelead
  • Exelixis
  • Exothera
  • Expression Therapeutics
  • FairJourney Biologics
  • FamiCord
  • Fapon Biopharma
  • Farmabios
  • Faron Pharmaceuticals
  • FinVector
  • Flagship Pioneering
  • Flash Therapeutics
  • FloDesign Sonics
  • FluGen
  • For?Robin
  • Forecyte Bio
  • Forge Biologics
  • Formycon
  • Forum for Innovative Regenerative Medicine 
  • Fred Hutchinson Cancer Research Center
  • Freeline Therapeutics
  • French Tech Sovereignty
  • Fresenius Kabi
  • FUJIFILM Diosynth Biotechnologies
  • Fusion Antibodies
  • GAIA BioMedicine
  • Gamida Cell
  • GBI (Formerly Goodwin Biotechnology)
  • GC Cell 
  • GC Pharma
  • GE Healthcare
  • Gedeon Richter
  • GemPharmatech
  • GeneCraft
  • GeneCure Biotechnologies
  • Genenta Science
  • Genentech
  • GeneOne Life Sciences
  • Geneos Therapeutics
  • GeneQuantum Healthcare
  • GeneQuine Biotherapeutics
  • Genethon
  • Genexine
  • Genezen
  • GenIbet Biopharmaceuticals
  • Genmab
  • Genome & Company
  • Genopis
  • Genovior 
  • Genprex
  • GenScript ProBio
  • GenSensor
  • GentiBio
  • Genuv
  • GHO Capital
  • GigaGen
  • Gilead Sciences
  • Ginkgo Bioworks
  • Gladstone
  • Gland Pharma
  • GlycoSeLect 
  • Government of Canada
  • Government of Europe
  • Government Pharmaceutical Organization (Thailand)
  • GP Pharm
  • Grand River Aseptic Manufacturing (GRAM)
  • Great Ormond Street Hospital for Children
  • Great Point Partners
  • Green Cross LabCell
  • GreenLight Biosciences
  • GreenPak Biotech
  • Greffex
  • Grenoble Hospital 
  • Griffith University
  • GSK
  • GTP Bioways (formerly VBI Therapeutics)
  • GTP Technology
  • Gubra
  • HaemaLogiX
  • HALIX 
  • Hangzhou Redox BIO
  • Hanmi Pharmaceutical
  • Hansa Biopharma 
  • Harbin Hou pu Tong tang Biotechnology 
  • Harbour BioMed
  • Harpoon Therapeutics
  • Harvard University
  • HDT Bio
  • Heidelberg Pharma
  • Helixmith
  • Helvetic BioPharma
  • Hemogenyx
  • Hepatic Cell Therapy Support
  • Hikma Pharmaceuticals
  • Hile Bio-Technology
  • Hilleman Laboratories
  • Histocell (Acquired by Noray)
  • Hitachi
  • HiTech Health
  • HK inno.N
  • Hong Kong Institute of Biotechnology
  • Hookipa Biotech
  • Horizon Discovery 
  • Horizon Pharma
  • Horizon Therapeutics
  • Houston Methodist Research Institute
  • Hubei Yuyang Pharmaceutical
  • Humanigen
  • Hummingbird Bioscience
  • Hybio Pharmaceutical
  • Hycult Biotech
  • HYGEIA
  • I-Mab Biopharma
  • IAVI 
  • IBC Generium
  • IBI-Lorenzini
  • Icagen
  • Ichnos Sciences
  • ID Pharma
  • IDT Biologika
  • Ikarovec
  • Immatics
  • Immune Pharmaceuticals
  • Immunitas Therapeutics
  • ImmunoCellular Therapeutics
  • Immunocore
  • ImmunoGenesis
  • Immunome 
  • Immunomedics
  • ImmunoTek Bio Centers
  • Immutep (formerly Prima Biomed)
  • Imperial College London
  • Imperial Innovations
  • In3Bio
  • INADcure Foundation
  • IncoCell Tianjin
  • Indapta Therapeutics
  • Indian Immunologicals
  • IndyGeneUS AI
  • InflaRx
  • Inhibrx
  • InnoBation Bio
  • Innoputix
  • Innovative Biotech
  • Innovative NeuroTechnologies
  • InnovaVector
  • Inovio Pharmaceuticals
  • Inpac Probiotics 
  • INSERM-ANRS
  • Insight68
  • Institut Pasteur de Dakar
  • Institute for Research
  • Integrated DNA Technologies
  • Integrity Bio
  • IntellectiveBio
  • International AIDS Vaccine Initiative 
  • International Consortium
  • International Stem Cell Corporation
  • International Vaccine Institute (IVI)
  • Intervacc
  • Invetech
  • Iovance Biotherapeutics
  • iProgen Biotech
  • IQVIA
  • IsoPlexis
  • Italian Biochemical Institute Giovanni Lorenzini
  • IUCT Oncopole
  • Iveric Bio
  • Ixaka
  • JAFRAL
  • Japan Tissue Engineering
  • Japanese Society for Regenerative Medicine
  • Jeneil Biotech
  • JHL Biotech
  • Jiangsu Puxin Biopharmaceutical
  • Jikei University School of Medicine
  • Jitsubo 
  • Jo Lab
  • John Hopkins University
  • Johnson & Johnson
  • JOINN Biologics
  • JOINN Laboratories
  • Jubilant HollisterStier
  • Juno Pharmaceuticals
  • Junshi Biosciences
  • Just Biotherapeutics
  • Just-Evotec Biologics
  • JW CreaGene
  • JW Therapeutics
  • KABS Laboratories
  • KAHR Medical
  • Kamat Pharmatech
  • Kanaph Therapeutics
  • Kanda BioTech
  • Kaneka Eurogentec
  • Karolinska Institutet 
  • KBI Biopharma
  • Kemwell Biopharma
  • Kiadis Pharma 
  • Kidswell Bio
  • Kineta
  • Kite Pharma
  • Kodiak Sciences
  • KOLON Life Science
  • KP Pharmaceutical Technology
  • KPC
  • KriSan Biotech
  • KUBio
  • Kun Tuo Medical Research and Development
  • KURE.AI
  • Kytopen
  • L-GAM
  • Labcorp
  • Laboratorios Zepol
  • Lacer 
  • LakePharma
  • LamKap Bio
  • LAMPIRE Biological Laboratories
  • Landau Biotechnology
  • LaNova Medicines
  • Lava Therapeutics
  • Leads Biolabs
  • Leanbio
  • LEUKOCARE
  • Levena Biopharma
  • Li Xiulan
  • Life Biosciences
  • Lifera
  • LIfT BioSciences
  • Liminal BioSciences (formerly Prometic Life Sciences)
  • Limula
  • lino Biotech
  • Lipum 
  • List Biological Laboratories
  • LNC Therapeutics
  • LogicBio Therapeutics
  • Lokon Pharma
  • LongBio
  • Lonza
  • LOTTE BIOLOGICS
  • Lubrizol Life Science
  • LucasPye BIO
  • Luina Bio
  • Lupin
  • Lykan Bioscience
  • Lyophilization Services of New England
  • Lyophilization Technology
  • Lysogene
  • Mab-Venture Biopharma
  • Mabion
  • MabPlex
  • MAbSilico
  • mAbxience
  • MacroGenics
  • Malvern Panalytical
  • Massachusetts Eye and Ear
  • Massachusetts Institute of Technology (MIT)
  • MassBiologics
  • MaSTherCell
  • Matica Biotechnology
  • Max Planck Society, University Medical Center Göttingen
  • MaxiVAX
  • Mayo Clinic
  • MD Anderson Cancer Center (The University of Texas)
  • Medeor Therapeutics
  • Medical Technologies Innovation Facility
  • Medigene
  • MedImmune
  • MEDINET
  • MEDIPOST
  • Medisun Holdings
  • Medix Biochemica
  • Meissa Vaccines
  • Memo Therapeutics
  • Menarini Biotech
  • Mendus
  • Merck
  • Merck Millipore
  • Meridian BioGroup
  • Meridian Bioscience
  • Meridian Life Science
  • Mesoblast
  • Metastagen
  • Meteoric Biopharmaceuticals
  • MGB Biopharma
  • Microbiome Therapeutics Innovation Group (MTIG)
  • MicroBiopharm Japan
  • MicrofluidX
  • Mila’s Miracle Foundation
  • MilliporeSigma
  • Milner Therapeutics Institute
  • Miltenyi Biotec
  • Minaris Regenerative Medicine
  • Minneapolis Medical Research Foundation 
  • Mitsubishi Gas Chemical Company
  • mk2 Biotechnologies, Technical University of Munich (TUM)
  • Moderna
  • Molecular Partners 
  • Morphotek
  • Multispan
  • Multiverse Pharma
  • Mundipharma
  • Mustang Bio
  • Mycenax Biotech
  • Mylab Discovery Solutions
  • Myrtelle
  • NAGASE & CO.
  • Najít Technologies
  • Namocell
  • Nan Fung
  • Nanotein Technologies
  • Naobios
  • National Cancer Institute
  • National Center for Advancing Translational Sciences 
  • National Center for Regenerative Medicine
  • National Health Research Institutes 
  • National Heart, Lung and Blood Institute
  • National Institute of Allergy and Infectious Diseases 
  • National Institute of Health (NIH)
  • National Resilience
  • Nature Technology
  • Navrogen
  • NBE-Therapeutics
  • Neogen TC
  • NeoProgen
  • Neovacs
  • NeoVentures Biotechnology 
  • Neuland Laboratories
  • NeuroFx
  • NEUWAY Pharma 
  • NextCell Pharma
  • Nikon CeLL innovation
  • Nitto Avecia
  • NIZO
  • Nobelpharma
  • North Carolina State University
  • Northway Biotech
  • Nouscom
  • NovalGen
  • Novartis
  • Novasep
  • Novavax
  • Novex Innovations
  • NovoCodex Biopharmaceuticals
  • Novozymes
  • Nucleus Biologics
  • Numab Therapeutics
  • Nykode Therapeutics
  • NYU Langone Health
  • OBI Pharma
  • OBiO Technology
  • Octane Biotech
  • Ocugen
  • Oculogenex
  • Odimma Therapeutics
  • Odylia Therapeutics
  • Ology Bioservices
  • Olon
  • Omeros  
  • OmniaBio
  • Oncodesign
  • OncoOne
  • OncoQuest
  • OncoResponse
  • OncoVent
  • Ondek
  • Ono Pharmaceutical
  • OPM Biosciences
  • Oragenics
  • Orchard Therapeutics
  • Orgenesis 
  • Osaka University
  • OSE Immunotherapeutics
  • Osivax 
  • Otsuka Pharmaceutical
  • Oxford BioMedica
  • Oxford BioTherapeutics
  • Oxford Genetics
  • Oxford MEStar 
  • OXGENE
  • Pace Life Sciences
  • PackGene Biotech
  • PaizaBio
  • Pall
  • Panacea Biotec
  • Panacea Pharmaceuticals
  • PanCELLa
  • Panolos Bioscience
  • Paragon Bioservices
  • Paras Biopharmaceuticals
  • Parker Institute for Cancer Immunotherapy
  • Passage Bio
  • PATH
  • PCI Pharma Services
  • PCT
  • Peking University Biologics
  • Peter MacCallum Cancer Centre
  • Petrovax
  • Pfizer
  • Pfizer CentreOne
  • Phanes Therapeutics
  • PharmAbcine
  • PharmaBio
  • PharmaCell
  • Pharmadule Morimatsu
  • PharmaZell
  • Pharmicell
  • PhaseBio Pharmaceuticals
  • pHion Therapeutics
  • Pierre Fabre
  • Pinteon Therapeutics
  • Pionyr Immunotherapeutics
  • Piramal Pharma Solutions
  • PlasmidFactory
  • Pluristyx
  • Polaris Pharmaceuticals 
  • Polpharma Biologics
  • POLYGON Therapeutics
  • Polyplus
  • POLYVAC
  • Portola Pharmaceuticals
  • Porton Advanced Solutions
  • Precirix 
  • Precision NanoSystems
  • Prestige Biologics
  • Prevail Therapeutics
  • Probiodrug
  • ProBioGen
  • Profacgen
  • Profectus BioSciences
  • Prokarium
  • Propanc Biopharma
  • Proteon Therapeutics
  • ProteoNic
  • Protexin
  • Provia Labs
  • PsiVac
  • PTC Therapeutics 
  • PX'Therapeutics
  • Quantoom Biosciences
  • Quell Therapeutics
  • Quratis
  • Radimmune Therapeutics
  • Rani Therapeutics
  • Rare Trait Hope Fund
  • Ray Therapeutics
  • RD-Biotech
  • Recipharm
  • Refana
  • ReForm Biologics
  • REGENXBIO
  • Regulus Therapeutics
  • ReiThera
  • Relief Therapeutics
  • Remedium Bio
  • ReNeuroGen
  • Rentschler Biopharma
  • Rentschler Fill Solutions
  • Replicate Bioscience
  • Resilience
  • Resolution Therapeutics
  • RevaTis
  • Revolo Biotherapeutics
  • RheinCell Therapeutics
  • RiboBio
  • Richter-Helm BioLogics
  • River Vision Development 
  • Roche Diagnostics
  • Rocket Pharmaceuticals
  • Rokote Laboratories Finland
  • RoosterBio
  • Roslin Cell Therapies 
  • RoslinCT
  • Royaltech Med
  • RVAC Medicines
  • Rznomics
  • SAB Biotherapeutics
  • Saiba Biotech
  • Sam Chun Dang Pharm
  • Samsung Bioepis
  • Samsung Biologics
  • San Raffaele Hospital
  • SanBio
  • Sandoz
  • Sanofi
  • Santen Pharmaceutical
  • Sarepta Therapeutics
  • Sartorius Stedim Biotech
  • SBT Instruments
  • Scancell
  • SCD
  • School of Chemical Engineering (part of University of Adelaide)
  • Scientific Protein Laboratories
  • ScinoPharm
  • Scorpion Biological Services
  • SD Biosensor
  • Selecta Biosciences
  • Selexis
  • Serendex Pharmaceuticals
  • Serum Institute of India
  • Servier
  • SGS
  • Shandong Luoxin Pharmaceutical
  • Shanghai Jiao Tong University
  • Sheba Medical Center 
  • Shenyang Sino-German Equipment Park
  • Shenzhen JYMed Technology
  • Shilpa Biologicals
  • Shire 
  • Shoreline Biosciences
  • Showa Denko
  • Siam Bioscience
  • Siegfried
  • SillaJen
  • Simris
  • Singota Solutions
  • Singzyme
  • Sino-German International Industrial Park
  • Sinorda Biomedicine
  • SIRION Biotech
  • Sistemic
  • SJL Partners
  • SK bioscience
  • Smart Cells Holdings
  • Snapdragon Chemistry
  • Sofpromed
  • Solid Biosciences
  • Sonnet BioTherapeutics 
  • Sorrento Therapeutics
  • Southern RNA 
  • Spicona
  • SpyBiotech
  • ST Pharm
  • Stand Up Therapeutics
  • Stanford University School of Medicine
  • STCube
  • Stelis Biosource
  • Stellar Biotechnologies
  • Stemmatters
  • Sterling Pharma Solutions
  • STgen Bio
  • Stoic Bio
  • Stratophase  
  • Sumagen
  • Sumitomo Dainippon Pharma
  • Summa Life Sciences
  • Sun Pharma
  • Surface Oncology 
  • Surrozen
  • Suzhou Kintor Pharmaceuticals
  • Suzhou Royaltech Med
  • SwiftScale Biologics
  • Symbiosis Pharmaceutical Services
  • Symphogen
  • Synaffix
  • SynCo Bio
  • Synimmune
  • Synklino
  • Synpromics
  • Synthace
  • Synthelis
  • T-knife
  • TaiMed Biologics
  • Taiwan Bio Therapeutics
  • Taiwan Liposome Company
  • Takara Bio
  • Takeda
  • Takeda Pharmaceuticals
  • Taron Solutions
  • TCR2 Therapeutics
  • TechInvention Lifecare
  • Tectron 
  • Telix Pharmaceuticals
  • Tenboron
  • TetraScience
  • Teva Pharmaceuticals
  • Tevogen Bio
  • Texcell
  • TG Therapeutics
  • The Coalition for Epidemic Preparedness Innovations 
  • The International Vaccine Institute (IVI)
  • The Leukemia & Lymphoma Society
  • The Michael J. Fox Foundation
  • The New Hope Research Foundation
  • The Parker Institute for Cancer Immunotherapy (PICI)
  • The Peter Doherty Institute for Infection and Immunity
  • The University Medical Center Göttingen (UMG)
  • The University of Adelaide
  • The University of Manchester
  • The US Department of Defence
  • The Wistar Institute
  • Themis
  • Theracell Advanced Biotechnology
  • Theragent
  • Theramex
  • Therapure Biopharma
  • Theravectys
  • Thermo Fisher Scientific
  • ThermoGenesis (formerly known as Cesca Therapeutics)
  • Thousand Oaks Biopharmaceuticals
  • Tianjin Pharmaceutical
  • TiGenix
  • Tillotts Pharma 
  • Tizona Therapeutics
  • Tmunity Therapeutics
  • Tonix Pharmaceuticals
  • Toregem BioPharma
  • Touchlight
  • Touchlight Genetics
  • TRACON Pharmaceuticals
  • TrakCel
  • Transgene
  • Translate Bio
  • Transporin
  • TranXenoGen
  • Treadwell Therapeutics
  • Trefoil Therapeutics 
  • Trellis Bioscience
  • Tri-Institutional Therapeutics Discovery Institute 
  • Trianni
  • Trieza Therapeutics
  • TriLink BioTechnologies
  • TRIO Pharmaceuticals
  • Triphase Accelerator 
  • Trizell
  • Tsinghua University Innovation Center for Immune Therapy 
  • TUBE Biopharmaceuticals
  • TWi Pharmaceuticals
  • Twist Bioscience
  • TxCell
  • U.S. Department of Defense
  • uBriGene Biosciences
  • UGA Biopharma
  • UK Cystic Fibrosis Gene Therapy Consortium
  • UK Dementia Research Institute
  • UK Government
  • Ultragenyx Pharmaceutical
  • UNC Lineberger Comprehensive Cancer Center
  • Unique Biotech
  • Univercells
  • Univercells Technologies
  • University College London
  • University of Aberdeen
  • University of Birmingham
  • University of California
  • University of Leeds
  • University of Pennsylvania
  • University of Queensland
  • University of Reading
  • University of Sheffield
  • University of South Australia 
  • University of Tokyo 
  • Uppsala BIO
  • US Department of Defense
  • US government 
  • Vaccine Manufacturing and Innovation Centre
  • Vaccine Research Institute (VRI)
  • Vaccitech 
  • Vaccizone
  • ValenzaBio
  • Valerius Biopharma
  • Valneva 
  • Valo Health
  • Valo Therapeutics
  • Vanderbilt University Medical Center 
  • Vasculogics
  • Vaxart
  • VBI Vaccines
  • VDDI Pharmaceuticals
  • Vector BioMed
  • VectorBuilder 
  • Vectron Biosolutions
  • Veeva Systems
  • Versameb
  • Verseau Therapeutics
  • Vertex Pharmaceuticals
  • Vetter Pharma
  • VGXI
  • Vibalogics
  • VIDO
  • Vifor Pharma
  • Vigene Biosciences
  • Vineti
  • Vir Biotechnology
  • Viralgen
  • Virchow Biotech
  • Virion Therapeutics
  • ViroCell Biologics
  • Virovek
  • Viscofan
  • Vistria Group
  • VIVEbiotech
  • Voyager Therapeutics
  • VVector Bio
  • W.L. Gore & Associates
  • WACKER
  • Waisman Biomanufacturing
  • Walvax Biotechnology
  • Warburg Pincus
  • Wheeler Bio
  • Winclove Probiotics
  • WuXi AppTec
  • WuXi Biologics
  • Wuxi Griffin
  • Xbrane Biopharma
  • Xenetic Biosciences
  • XL-protein 
  • Xpress Biologics
  • Xyphos Biosciences
  • Yapan Bio
  • Yinjia Biosciences
  • Yposkesi
  • Yuhan
  • Zealand Pharma 
  • Zelluna Immunotherapy
  • Zencore Biologics
  • Zhejiang Hisun Pharmaceutical
  • Zhejiang Teruisi Pharmaceutical
  • Zhittya Genesis Medicine
  • Zumutor Biologics
  • Zymeworks
  • ZyVersa Therapeutics

Methodology

 

 

Loading
LOADING...

Table Information